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Abstract
Moyamoya disease (MMD) is a rare cerebrovascular disease characterized by progressive spontaneous bilateral 
occlusion of the intracranial internal cerebral arteries (ICA) and their major branches with compensatory capillary 
collaterals resembling a “puff of smoke” (Japanese: Moyamoya) on cerebral angiography. These pathological altera-
tions of the vessels are called Moyamoya arteriopathy or vasculopathy and a further distinction is made between 
primary and secondary MMD. Clinical presentation depends on age and population, with hemorrhage and ischemic 
infarcts in particular leading to severe neurological dysfunction or even death. Although the diagnostic suspicion 
can be posed by MRA or CTA, cerebral angiography is mandatory for diagnostic confirmation. Since no therapy to 
limit the stenotic lesions or the development of a collateral network is available, the only treatment established so 
far is surgical revascularization. The pathophysiology still remains unknown. Due to the early age of onset, familial 
cases and the variable incidence rate between different ethnic groups, the focus was put on genetic aspects early on. 
Several genetic risk loci as well as individual risk genes have been reported; however, few of them could be repli-
cated in independent series. Linkage studies revealed linkage to the 17q25 locus. Multiple studies on the association 
of SNPs and MMD have been conducted, mainly focussing on the endothelium, smooth muscle cells,  cytokines 
and growth factors. A variant of the RNF213 gene was shown to be strongly associated with MMD with a founder 
effect in the East Asian population. Although it is unknown how mutations in the RNF213 gene, encoding for a 
ubiquitously expressed 591 kDa cytosolic protein, lead to clinical features of MMD, RNF213 has been confirmed 
as a susceptibility gene in several studies with a gene dosage-dependent clinical phenotype, allowing preventive 
screening and possibly the  development of new therapeutic approaches. This review focuses on the genetic basis 
of primary MMD only.
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Definition
Moyamoya disease (MMD), first described in 1957 by 
Takeuchi and Shimizu [1] and characterized as a new dis-
ease entity in 1969 by Suzuki and Takaku [2], is a rare 
cerebrovascular disease characterized by progressive 
spontaneous bilateral occlusion of the intracranial internal 
carotid arteries (ICA) and their major branches (middle 
cerebral artery, MCA, and anterior cerebral artery, ACA) 
with compensatory capillary collaterals as an expression 
of pathologically increased angiogenic activity [3] resem-
bling a “puff of smoke” (Japanese: Moyamoya) on cerebral 
angiography. Moyamoya collaterals may disappear with 
development of meningeal collaterals from the external 
cerebral arteries (ECA). Intracranial aneurysms are often 
found in patients with MMD. These pathological altera-
tions of the vessels are called Moyamoya arteriopathy 
(MMA) or vasculopathy (MMV). A further distinction is 
made between primary and secondary MMD: primary or 
idiopathic MMD is defined as bilateral stenosis of ICA 
and their major branches that is neither of arteriosclerotic 
nor of inflammatory origin. The pathophysiology remains 
unknown. Similar vascular changes may also occur in the 
kidney, heart and/or other organs. Secondary MMD (also 
known as “moyamoya syndrome” or “quasi moyamoya dis-
ease”) is described as the typical angiographic findings 
associated with other autoimmune (e.g., Graves disease, 
systemic lupus erythematosus [4]), vascular (atheroscle-
rosis), congenital (NF1 [5], Down syndrome [6], Turner 
syndrome [7]) and hematologic (e.g., sickle cell disease 
[8]) disorders. This review focuses on the genetic basis of 
primary MMD only.
Epidemiology
The incidence of MMD has major ethnic differences. 
Initially, MMD was considered a specific disease in the 
Japanese population after its first description by Takeuchi 
and Shimizu [1]. MMD has now been observed in peo-
ple of many ethnic backgrounds throughout the world, 
preferring the Asian race, primarily Japanese [9]. Baba 
et al. described a detection rate per year of 0.94/100.000 
people and a prevalence of 10.5/100.000 people between 
2002 and 2006 in Hokkaido, Japan. The ratio of female 
to male patients was 2.18. Two peaks for age of onset 
were described: between 5 and 9 years and between 45 
and 49 years. Familial history was observed in 15.4% of 
patients. The detection rate and prevalence was higher 
than previously described, which has been interpreted as 
a result of better diagnostic possibilities, rather than an 
actual increase of the incidence [10]. The average detec-
tion rate per year and the prevalence in the Nanjing pop-
ulation (China) between 2000 and 2007 was described 
as 0.43/100.00 and 3.92/100.000 by Miao et  al. [11]. 
In Korea, the incidence from 2007 to 2011 was 1.7 to 
2.3/100.000, and the prevalence in 2011 was 16.1/100.000 
[12]. MMD incidence in Japan, Korea, and China is higher 
than in Europe and North America [13]. In the USA, inci-
dences per 100.000 patient years ranged from 0.05 [13, 
14] in Iowa to 0.17 in Hawaii [13, 15]. The incidence rate 
of MMD among Asian Americans living in California is 
comparable to the incidence in Asia (0.28/100.000). Eth-
nic differences in MMD incidence appear to be maintained 
after immigration to the USA, with Asian Americans hav-
ing the highest incidence [16]. Few population-based data 
are available from Europe, e.g., an incidence of 0.047 per 
100.000 person years in Denmark [17]. The epidemiology 
in Western countries seems to differ from Asian countries 
and is characterized by a more pronounced female prepon-
derance and a higher age at onset of disease [18].
Clinical Presentation and Natural History
Symptoms are mainly attributed to changes in the cerebral 
blood flow resulting from stenosis of the ICA (ischemia) and 
from the fragility of the compensatory capillary collater-
als (hemorrhage). The clinical manifestation seems to vary 
among geographic regions. In a Japanese cohort, the per-
centage of hemorrhagic manifestation was 21.0% with only 
one peak at 35–39 years, whereas the percentage of ischemic 
manifestation was 57.4% with two peaks: one at 5–9 years 
and the other at 45–49 years. Hemorrhagic manifestation is 
found in < 5% and 40% of cases amongst the pediatric and 
adult Japanese MMD population [10, 19]. In a Korean sur-
vey, the major clinical manifestations were ischemia in chil-
dren (61.2% vs. 25.4% in adults) and hemorrhage in adults 
(62.4% vs. 9.1% in children). Among patients with ischemic 
symptoms, adults were more likely to have infarction than 
pediatric patients (80% vs. 39%) and pediatric patients were 
more likely to have transient ischemic attack (TIA) (61% 
vs. 25%) [20]. The phenotype in Western countries seems 
to differ from the phenotype in Asian countries and is char-
acterised by a lower likelihood of hemorrhagic stroke as 
an adult [18]. In the USA, adults have much lower rates of 
hemorrhage as a presenting symptom (20%). The majority 
of affected adults and children in the USA presented with 
ischemic symptoms [6, 21]. Among European Caucasian 
MMD patients, 81% initially presented with ischemic and 
8.5% with hemorrhagic manifestation. The rate of hemor-
rhagic manifestation amongst the pediatric group (≤ 18) 
was slightly higher than in the adult group (12% vs. 7.8%) 
[19]. According to the International Pediatric Stroke Study, 
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MMD accounted for 8% of strokes in Caucasian children 
[22]. Another frequent symptom is headache, presumably 
due to dilatation of meningeal collateral vessels [23], as well 
as movement disorders [24]. Approximately 17.8% of Japa-
nese patients are asymptomatic [10]. The natural history of 
untreated MMD is poor with a 73% rate of major deficit or 
death over two years following diagnosis in children [25]. 
The clinical symptomatology in MMD patients can be strati-
fied by the Berlin grading system, which combines digital 
subtraction angiography (DSA), magnetic resonance imag-
ing (MRI) and cerebrovascular reserve capacity (CVRC) as 
dependent factors associated with the occurrence of clinical 
symptoms [26].
Neuroimaging
Diagnosis of MMD requires bilateral stenosis/occlusion 
of the ICA and its major branches as well as compensa-
tory capillary collaterals, shown on cerebral angiography. 
Unenhanced computed tomography (CT) may show multi-
ple and bilateral cortical and subcortical low density areas. 
Moyamoya vessels appear as flow voids on MRI. MRI often 
shows parenchymal ischemic lesions (Fig. 1A). Although 
CT-angiography or MR-angiography may pose the diagnos-
tic suspicion, DSA is necessary to establish the diagnosis, 
identifying suitable vessels for bypass-surgery and to spot 
aneurysms (Fig. 1C). Cerebral blood flow (CBF) studies by 
positron emission tomography (PET) can identify areas of 
low perfusion with aggravation after acetazolamide chal-
lenge (causes vasodilatation, evaluates reserve capacity of 
cerebral blood flow and identifies areas at risk for future 
infarction, Fig. 1B).
Treatment
No treatment can stop or reverse the primary disease pro-
gress. Recurring ischemic symptoms and impaired cerebral 
blood flow are the main indicators for treatment [27], but 
also determine the severity of symptoms and the risk of 
intervention [26, 28]. For asymptomatic patients, rand-
omized trials are still missing to determine therapeutic pro-
cedures. Medical treatment with platelet inhibitors, antico-
agulants, calcium channel blockers etc. has not proven to be 
of benefit, yet platelet inhibitors are broadly used to prevent 
ischemic insults.
Three different surgical revascularization methods are 
applied: direct revascularization by bypass surgery (e.g., 
STA-MCA-bypass, STA = superficial temporal artery; 
Fig.  1D + E), indirect and combined revascularization 
[29–32]. Currently, various surgical techniques are applied. 
Given the lack of randomised trials, there is neither clear 
evidence for the optimal timing of intervention nor which 
of  these techniques is the most efficacious. However, cur-
rent studies strongly indicate that surgical revascularization 
should be applied in patients with MMD of all age popula-
tions, if technically feasible [29].
Pathological Hallmarks
As mentioned above, MMD is mainly characterized by pro-
gressive spontaneous bilateral occlusion of the terminal ICA 
and their major branches with compensatory capillary col-
laterals as an expression of pathologically increased angio-
genic activity [3]. Histological examinations of the steno-
occlusive arteries revealed fibrocellular thickening of the 
intima caused by proliferation of smooth muscle cells (SMC) 
with abnormal findings such as irregular undulation of the 
internal elastic lamina and significantly thinner media with 
absence of atheromatous plaques [33–35]. Moyamoya ves-
sels are dilated perforating arteries, including preexisting 
and newly developed vessels as an expression of pathologi-
cally increased angiogenesis, vasculogenesis and arteriogen-
esis [36, 37]. In fact, MMD patients show more frequent 
angiogenesis events compared to patients with chronic cer-
ebral ischemia of other etiologies such as atherosclerotic 
cerebrovascular disease (ACVD) [38, 39]. However, these 
newly formed vessels show impaired blood–brain barrier 
function, loss of endothelial cell integrity [40, 41] and vari-
ous histopathological changes including fragmented elastic 
lamina, attenuated media, fibrin deposits in the wall and 
microaneurysms related to increased flow [6, 33, 42, 43]. 
Rupture of microaneurysms as well as increased fragility 
and leakage of the Moyamoya vessels are the main source 
of hemorrhagic stroke in MMD. Different dilatation patterns 
of the collaterals may be associated with an ethnic difference 
in the clinical presentation of MMD [44]. Thrombosis and 
collapse of the artery lumen can also be seen in the Moy-
amoya vessels, which could be the cause of ischemic symp-
toms [6, 33, 42]. Leptomeningeal vessels show attenuation 
or disruption of the internal elastic lamina and fibrous inti-
mal thickening. These vessels seem not to be newly formed 
but are merely dilated preexisting vessels [45].
Given these pathological hallmarks, mutations of hetero-
geneous groups of genes could possibly be involved in the 
development of MMD. We speculate that mutations may lie 
in genes which
1. Affect smooth muscle cells (SMC) and
2. Affect the extracellular matrix (ECM), both leading to 
fibrocellular thickening of the intima and attenuation of 
the media
3. Lead to increased vascular plasticity and induce angio-
genesis, vasculogenesis and arteriogenesis
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4. Cause vessel fragility and vessel leakage and possibly 
weaken intra-extracellular contacts (could also be a 
result of point 3)
5. Are affected differently in various ethnic groups, 
explaining ethnic differences in vascular changes and 
disease patterns, such as frequency of intracerebral hem-
orrhage (point 4), different vessel occlusion patterns 
(point 1 + 2) and different collateral pathways (point 3).
Genetics of MMD and Pathophysiological 
Features
The pathophysiology of MMD still remains unknown. MMD 
seems most likely to be a multifactorial disease, to which dif-
ferent factors such as environmental influences and genetic 
aspects contribute with varying degrees of impact. Different 
environmental factors such as radiation [46], bacterial infec-
tion [47], varicella zoster virus (VZV) [48], Epstein-Barr 
virus (EBV) and cytomegalovirus (CMV) [49] infections 
have been described to play a role in the pathophysiology of 
MMD. However, they could not be detected in the major-
ity of affected patients. The incidence of MMD in patients 
of Asian descent living in non-Asian countries is compara-
ble to the incidence in Asia [16], rendering a geographical 
or environmental influence unlikely. The concentration of 
affected patients in East Asian countries as well as familial 
cases strengthen the hypothesis that genetic factors have a 
major role in the development of the disease.  Genetic vari-
ants found more frequent in some ethnic groups than oth-
ers may explain the variable prevalence of MMD. Recently, 
genetic approaches have increasingly been used to clarify the 
pathogenesis of the disease—with success. In the following, 
we present the genetic aspects of the pathophysiology in the-
matic subgroups. Figure 2 summarizes the genetic findings 
in MMD focusing on the different methodical approaches 
that have been used.
The Analysis of Epidemiological Data, 
Inheritance Patterns, and Data from Family 
Cases
The analysis of epidemiological data, inheritance patterns 
and data from family cases already suggests that genetic 
factors play a major role in the development of MMD. As 
described above, detection rate and prevalence rate vary 
among different ethnic populations, being the highest in 
East Asian countries. Family cases account for up to 15.4% 
of cases in Japan with major changes in epidemiological 
data within familial groups: the female preponderance was 
significantly more prominent in the familial than in the spo-
radic group with a male/female ratio of 1:5 vs. 1:1.6. Mean 
age at onset was significantly lower in familial (11.8 ± 11.7) 
than in sporadic cases (30.0 ± 20.9). In 8 parent–offspring 
pairs, mean age at onset was significantly lower in the 
second (7.2 ± 2.7) than in the first generation (30.7 ± 7.5) 
[10]. It was, hence, even suggested that familial MMD-
cases could be associated with genetic anticipation, which 
would confirm a genetic pathophysiology [50]. To further 
determine the pattern of inheritance, Mineharu et al. exam-
ined 15 highly aggregated Japanese families (52 patients; 
38 women and 14 men): all types of transmission between 
generations were observed and the mode of inheritance of 
familial MMD was reported to be autosomal dominant with 
incomplete penetrance with an increased rate of maternal 
transmission (3.44:1) [51]. An analysis of twin pairs suffer-
ing MMD revealed monozygotic predominance (4.7–7.5:1) 
with 5 of the 12 analyzed monozygotic twins showing dis-
cordant phenotypes [51]. This observation supports the con-
cept of environmental factors triggering MMD in susceptible 
individuals. Recently, a population-based aggregation study 
in Korea, conducted to quantify the familial risk of MMD, 
was published by Ahn et al. [52]: by using a national data 
base, a cohort of 21.940.795 study subjects constituting 12 
million families has been  observed for a familial occurrence 
of MMD from 2002 to 2017. Incidence risk ratios (IRR) 
were calculated as the MMD incidence in individuals with 
affected first-degree relatives divided by the incidence in 
those without affected first-degree relatives. Summarized, 
the familial risk / IRR for MMD was 132 × higher in individ-
uals with than in those without affected first-degree relatives, 
with 3.2% of the former and 0.02% of the latter developing 
MMD. The familial risk showed age dependence with a high 
peak in the younger age group, which then reduced with 
increasing age. Familial risk (IRR; incidence/104person-
years) markedly increased with the degree of genetic relat-
edness, being highest in individuals with an affected twin 
Fig. 1  MRI, PET, and DSA findings in patients with MMD. A: MRI 
(T1) shows multi-stage infarction with extensive chronic infarcts 
frontally and in the left basal ganglia (▷) B: PET-MR brain examina-
tion with O-15-H2O (at baseline (Bq/ml), under acetazolamide chal-
lenge (Bq/ml) and calculated relative reserve capacity (%)) shows 
bilateral aggravation of the cerebrovascular reserve capacity in both 
ACA and MCA perfusion areas after acetazolamide challenge (▷). 
C: Supraaortal DSA (left ICA, upper row) shows supraophthalmic 
stenosis/occlusion of ICA (▷) with multiple hypertrophic Moy-
amoya collaterals (*) and restricted distal perfusion of ACA and 
MCA (#). In comparison, the lower row shows a DSA (left ICA) of 
a healthy patient. D: Postoperative angiography (anterior projection) 
of the left ECA after STA-MCA bypass surgery demonstrating bypass 
graft patency (▷). E: Illustration of STA-MCA bypass (red circle). 
Source figure E: 10.1161/STROKEAHA.117.018563; Courtesy of 
P. Vajkoczy. PET-MR was performed by the Department of Nuclear 
Medicine, Charité – Universitätsmedizin Berlin, Berlin, Germany. 
MRI and DSA was performed by the Department of Neuroradiology, 
Charité – Universitätsmedizin Berlin, Berlin, Germany
◂
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(1254.1; 230.0), followed by a sibling (212.4; 35.6), then 
mother (87.7; 14.4) and father (62.5; 10.4), indicating that 
genetic predisposition is the prevailing trigger in MMD 
pathogenesis [52]. Data on family cases in Caucasians are 
very rare and limited to a few case reports [53, 54]. The 
later onset and the lower familial occurrence demonstrated 
in Western patients may be accounted for the higher influ-
ence of genetic factors in Asian populations [18].
Genetic Linkage Studies
Genetic linkage is the tendency of genetic loci that are 
positioned close together to be inherited together. In link-
age analyses, the segregation of traits and diseases in 
families can be compared with the segregation of alleles 
of certain markers in meiosis. Genetic linkage analyses 
use the phenotypic findings of pedigree analyses and 
investigate their linkage to a genetic locus. If these loci 
appear to be linked to affected patients, it is assumed that 
disease-causing genes are located nearby. The statistical 
measure for linkage certainty is the logarithm of the odds 
score (LOD score). A linkage is considered significant 
if the LOD score is above 3. A LOD score of -2 or less 
indicates no linkage. Once the chromosomal subregion 
for a disease locus has been determined with a linkage 
analysis, databases can be searched for candidate genes 
in this region [55, 56]. Several linkage analyses regard-
ing MMD have reported different linked regions. Link-
age analyses under the assumption of autosomal recessive 
inheritance revealed that the D3S2387 and D3S3050 loci 
on chromosome 3 showed parametric LOD scores > 1.0. 
Nonparametric linkage analyses showed a nonparametric 
LOD score > 1.96 at loci between D3S2387 and D3S3050. 
These two loci are both located on chromosome 3p24.2-
p26, a region that contains genes responsible for von Hip-
pel-Lindau syndrome and Marfan syndrome [57]. Inoue 
et al. reported linkage of the marker D6S441 (6q25) to 
MMD [58]. Sakurai et al. reported significant evidence 
for linkage to 8q23 (D8S546) with a maximum LOD 
score of 3.6 and suggestive evidence for linkage to 12p12 
(D12S1690) with a maximum LOD score of 2.3 by per-
forming a genome-wide linkage analysis [59]. Yamauchi 
et al. described a new location of candidate genes causing 
familial MMD on chromosome 17q25. An initial screen-
ing of 4 Japanese families with 10 microsatellite markers 
Fig. 2  Overview of the genetic 
findings in MMD with a 
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showed a positive maximum LOD score of 0.32 at the 
D17S784 marker on chromosome 17q25. Then, detailed 
analyses of 24 families with 9 additional markers around 
D17S784 yielded a cumulative maximum LOD score of 
3.11 for the marker D17S939 using a dominant transmis-
sion model. Multipoint linkage analysis revealed that the 
gene causing MMD was most likely to lie in the 9-cM 
interval between D17S785 and D17S836, with a maxi-
mum LOD score of 4.58 [60]. Shortly after this linkage 
has been described, Nanba et al. selected and sequenced 
9 of 65 genes identified in the 9-cM region of D17S785-
D17S836 in a pedigree of familial MMD, whose DNA 
samples showed a linkage to this region. No mutation 
was found in these genes [61]. Nevertheless, chromosome 
17q25 remained a target region since only few genes in 
this region have been analyzed. Mineharu et al. suggested 
a major gene locus for dominant MMD on chromosome 
17q25.3 by genome-wide linkage analysis. Significant 
linkage was observed on chromosome 17q25.3 (D17S704), 
with maximum LOD scores of 6.57 (narrow classification 
including definite MMD according to the RCMJ criteria) 
and 8.07 (broad classification, including any steno-occlu-
sive lesions around the terminal portions of the ICAs, 
either unilaterally or bilaterally, even without findings 
of MMD vessels). The critical MMD gene location was 
defined within a 3.5-Mb region from D17S1806 to the end 
of chromosome 17q, encompassing 94 annotated genes. 
A mutational analysis of 4 candidate genes in this region 
was performed (BAIAP2, TIMP2, RAC3 and RAB40B), 
showing no significant mutations related to MMD. The 
locus reported by Yamauchi et al. [60] seemed not to be 
identical to the newly reported region. Moreover, the pre-
viously described loci 3p24-p26.18 and 8q23 [57, 59] sat-
isfied the linkage exclusion criteria (LOD score <  − 2.0) 
[62]. Liu et al. further increased the LOD score of 8.07 
for 17q25.3 to 9.67 and the linkage signal was narrowed 
to a 2.1 Mb region [63]. Linkage to the 17q25.3 locus 
has been further confirmed in several studies. Kamada 
et al. performed a linkage analysis focused on previously 
reported candidate loci (3p, 6q, 8q, 12p and 17q25). No 
locus with significant linkage with LOD > 3 could be con-
firmed. A suggestive linkage for the microsatellite maker 
D17S784 on chromosome 17q25 with a LOD score of 2.4 
was observed [64]. Liu et al. confirmed linkage to 17q25.3 
by genome-wide linkage analysis using 382 markers in 8 
MMD families. Fine mapping revealed a 1.5-Mb locus 
bounded by D17S1806 and rs2280147, harboring 21 genes 
[65]. In summary, a number of linkage analyses have been 
conducted using either parametric or non-parametric 
methods. Five loci have been linked to MMD: 3p24.2-
p26, 6q25, 8q23, 12p12, and 17q25. Except for the 17q25 
locus, none of these loci has been confirmed, leading to 
the assumption that this locus may contain genes respon-
sible for the development of MMD.
Genetic Association Studies and Sequencing
Until the year 2000, the primary method of investigation 
in the discovery of genes for human diseases was through 
inheritance studies of genetic linkage in families. Highly 
useful towards single gene disorders, the results of genetic 
linkage studies in complex diseases proved hard to repro-
duce [66]. A suggested alternative to linkage studies was the 
genetic association study [67]. Association studies are obser-
vational case–control studies of genetic variants and markers 
in sporadic and/or familial cases to identify association with 
a trait, investigating whether an allele of a gene is found 
more often in individuals with the phenotype or disease of 
interest. Typically, association studies focus on association 
between single-nucleotide polymorphisms (SNPs) and dis-
eases. Genome-wide association studies (GWAS) investigate 
the entire genome instead of pre-specified genetic regions 
[68]. With its introduction in the mid-1970s, standardized 
DNA sequencing revolutionized the decoding of the human 
genome. Classic methods such as Sanger sequencing and 
the Maxim-Gilbert method were further developed into a 
series of new techniques (next generation sequencing, NGS), 
which nowadays allow the nucleotide sequence in a DNA 
molecule to be decoded much faster and more cost-effective. 
Sequencing allows to determine whether a gene or the region 
that regulates a gene contains changes, called mutations or 
variants, that are linked to a disorder. Multiple studies on 
the association of polymorphisms to MMD have been con-
ducted, mainly focussing on endothelium, smooth muscle 
cells, cytokines and growth factors. Sequencing revealed 
several new candidate genes, which further contributed to 
the pathophysiological knowledge about MMD.
The Human Leukocyte Antigen (HLA) System
The human leukocyte antigen (HLA) system is a group 
of proteins that are encoded by a gene complex called the 
major histocompatibility complex (MHC, located on chro-
mosome 6p21.3, encoding the class I HLA-A/B/C and class 
II HLA-DR/DQ/DP), responsible for the regulation of the 
immune system and identifying self versus non-self. HLA 
genes are highly polymorphic. In general, the inheritance 
of a disease-associated HLA allele is a risk factor that 
increases a patient’s likelihood of developing the disease 
[69]. HLA genes have been studied in Asian and Euro-
pean MMD patients and several associations have been 
described. One of the first HLA–MMD association studies 
conducted by Kitahara et al. revealed a significant associa-
tion with HLA-AW24, -BW46 and – BW54 with a relative 
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risk (RR) of 3.83, 6.50, and 3.58 in Japanese MMD patients 
and controls [70]. Aoyagi et al. performed HLA genotyping 
in Japanese MMD patients and controls, revealing a sig-
nificant positive association between MMD and HLA-B51 
with a RR of 3.7. The previously described HLA-AW24, 
-BW46 and -BW54 frequencies [70] did not differ between 
MMD patients and healthy controls [71]. Inoue et al. geno-
typed HLA class II gene alleles in unrelated Japanese MMD 
patients and controls, showing a significant positive associa-
tion between MMD and HLA-DQB1*0502 and a signifi-
cant negative association between MMD and DRB1*0405 
and DQB1*0401 with RRs of 3.27, 0.35, and 0.40 [72]. To 
confirm these results, Han et al. genotyped HLA class I and 
II alleles in Korean MMD patients and controls. The fre-
quency of the HLA-B35 allele was significantly increased 
in the MMD patients compared to the controls with a RR of 
4.2. HLA-B35 was most significantly increased in female 
patients with late-onset MMD. The above mentioned previ-
ous findings on HLA-B51, DQB1*0502, DRB1*0405, and 
DQB1*0401 in the Japanese cohort could not be replicated 
in this Korean cohort [73]. To investigate whether there is a 
difference in HLA class II association between familial and 
non-familial MMD patients, HLA class II alleles were geno-
typed in Korean children with MMD including familial cases 
and controls. The frequencies of HLA-DRB1*1302 (70.0%) 
and DQB1*0609 (40.0%) were significantly increased 
in familial MMD patients compared to both controls (vs. 
15.5%, odds ratio (OR) = 12.76; vs. 4.3%, OR = 14.67) and 
non-familial MMD patients (vs. 14.8%, OR = 13.42; vs. 
1.9%, OR = 35.33). There was no significant difference in 
the frequencies of HLA-DRB1 and -DQB1 alleles in non-
familial MMD patients vs. healthy controls [74]. To inves-
tigate HLA association in Caucasian patients, Kreamer 
et al. analyzed DNA of Caucasian patients (22 MMD + 11 
MMA). HLA-A, -B, and -DRB1 frequencies were compared 
with those of 13.386 German blood donors, whereas the 
HLA-DQB1 frequencies were compared with US American 
National Marrow Donor Program (NMDP) data from 15.470 
different Caucasian donors. Significant disease association 
was found for HLA-DRB1*03 (for all 33 MMD + MMA 
patients (RR 4.443) and for all 22 patients with MMD (RR 
5.391)) and for HLA-DRB1*13 (for all 33 patients (RR 
4.268) with a lower significant frequency in those patients 
with MMD (RR 4.277)). Moreover, HLA-A*02, HLA-B*08, 
and HLA-DQB1*03 showed lower significantly elevated fre-
quency in the 33 patients compared with the controls but 
not in the subgroup analysis. Despite HLA-DRB1*13, HLA 
markers previously described in the Asian literature were not 
replicable with high levels of significance: HLA-DQB1*05, 
-B35 and –AW24 only showed weakly significantly elevated 
frequencies in the Caucasian cohort [75]. More recently, 
Tashiro et al. identified HLA-DRB1*04:10 as a new risk 
allele and HLA-DRB1*04:10 – HLA- DQB1*04:02 as a risk 
haplotype in Japanese MMD patients. This result was again 
inconsistent with previous results [76]. However, the causa-
tive role of HLA polymorphisms in the molecular immu-
nopathogenesis of HLA associated diseases remains often 
poorly understood. Association may be due to HLA pres-
entation of altered or disease-triggering self-antigens, cross 
reactivity between self and foreign antigens or autoimmune 
response to self-antigens due to erroneous T cell selection 
[77], but a causal relationship in MMD is not understood 
yet. Altogether, the reported results and the fact that most 
findings could not be reproduced in independent studies 
may suggest that the association between HLA antigens and 
MMD differ between ethnic groups and that the different 
HLA alleles may not be significant susceptibility factors of 
MMD rather than genetic markers.
Smooth Muscle Cells (SMC) and Endothelial Nitric 
Oxide Synthase (eNOS)‑Derived Nitric Oxide (NO)
The major function of vascular smooth muscle cells (SMC) 
is to contract in response to the stretch resulting from pulsa-
tile blood flow. Endothelial nitric oxide synthase (eNOS)-
derived nitric oxide (NO) is one of the principal molecules 
in vasoregulation. Endothelial NO is responsible for regu-
lation of SMC and endothelium-dependent vasodilatation. 
Moreover, it is involved in the inhibition of leukocyte and 
platelet adhesion and attenuation of inflammatory mediators 
[78]. NO has protective as well as cytotoxic effects after cer-
ebral ischemia [79]. Therefore, an understanding of eNOS 
polymorphisms may help to explain variations in the clinical 
aspects of MMD. Park et al. conducted a case–control study 
on eNOS polymorphisms, suggesting that pediatric and 
adult-onset MMD may have different genetic backgrounds. 
In this study, 93 Korean MMD patients and 328 healthy 
controls were divided into pediatric (< 20 years) and adult 
(≥ 20 years) groups and further according to MRI findings 
into ischemic and hemorrhagic groups. No differences in 
four eNOS polymorphisms (eNOS − 922A > G, − 786 T > C, 
variable number of tandem repeat (= VNTR) polymorphism 
4a4b, and 894G > T) were observed between the combined 
MMD patient group and a control group. However, the 4a4b 
sequences were less frequent in the adult patient group and 
the ischemic group. Compared to the control group, the 
A-4b-G haplotype was seen more frequently in the adult 
patient group, suggesting that these genetic differences can 
affect age-specific clinical characteristics [80]. Following 
linkage analyses and confirming linkage to chromosome 
17q25.3, Liu et al. performed sequencing of  three genes 
encoded in this region, revealing one newly identified poly-
morphism, ss161110142 G/A, located at the transcription 
site of the Raptor gene. Raptor is associated with vascular 
SMC proliferation and intimal expansion. This polymor-
phism was genotyped in 34 families, revealing that every 
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affected individual in these tested families was found to 
carry the ss161110142 A allele, which showed complete 
segregation. The authors conducted a case–control asso-
ciation study for MMD performed in different ethnicities. 
The ss161110142 A allele was found much more frequent 
in cases than in the controls: 26% vs. 1% in the Japanese (90 
patients vs. 384 controls), 33% vs. 1% in the Koreans (41 
patients vs. 223 controls) and 4% vs. 0% in the Chinese (23 
patients vs. 100 controls). The allele was not found in the 
Caucasian group [63].
Matrix Metalloproteinases (MMPs) and Tissue Inhibitors 
of Metalloproteinases (TIMPs)
The balance between matrix metalloproteinases (MMPs) and 
tissue inhibitors of metalloproteinases (TIMPs) is critical for 
blood brain barrier (BBB) integrity [81], vascular injury and 
repair and by degrading the neurovascular matrix, MMPs 
promote BBB damage, oedema, and hemorrhage [82]. For 
example collagen IV, the essential substrate of MMP-9, is 
markedly affected in MMD vessel specimens compared to 
those obtained from atherosclerotic cerebrovascular disease 
patients [83]. Disruption of the balance between MMPs and 
TIMPs can result in aberrant ECM and SMC dynamics [84], 
which could facilitate the pathological hallmarks 1 and 2 
of MMD. Kang et al. investigated SNPs of the promoter 
regions, exon–intron junctions and the exons of the TIMP2 
and TIMP4 genes in 11 Korean familial MMD patients, 50 
Korean non-familial MMD patients and 50 control patients. 
The genes encoding TIMP2 and TIMP4 span chromosomes 
3p24.2-p26 and 17q25, which have been linked to familial 
MMD before [57, 60]. A significantly higher frequency of 
the heterozygous G/C genotype was found in the TIMP2 pro-
moter region at position −418 in familial MMD (rs8179090). 
This genotype was observed in 9 of 11 patients with famil-
ial MMD, in 16 out of 50 non-familial MMD patients and 
in 14 out of 50 control patients. OR between familial and 
non-familial MMD was 9.56 (95% confidence interval, 
1.85–49.48; p = 0.005) and 10.50 between familial MMD 
and control patients (95% confidence interval, 2.02–54.55; 
p = 0.001) with no significant differences between non-
familial MMD patients and controls. The base at position 
–418 corresponds to the site that binds the transcription 
factor Sp1. Thus, this variation may modify TIMP2 tran-
scription by modifying Sp1 binding [84]. Paez and Yama-
moto analyzed the genotype frequency of the same SNP in 
7 Japanese familial MMD patients, 41 non-familial MMD 
patients and 52 control patients. The results revealed only 
1 familial MMD patient (14%) with the G/C heterozygous 
genotype; the other 6 demonstrated the G/G homozygous 
genotype. There was no significant difference in the SNP 
frequencies of familial and non-familial MMD patients 
and controls, thus the results of Kang et al. could not be 
replicated in Japanese MMD patients [85]. The promoter 
polymorphism −418G > C in the TIMP2 gene could also not 
be replicated in another study with Japanese MMD patients 
from Mineharu et al. [62]. Roder et al. did not find a dif-
ferent frequency of the SNP rs8179090 C/G in the TIMP2 
gene in 40 European MMD patients and 68 controls [86]. Li 
et al. conducted an association study of 5 promoter SNPs in 
the MMP-2, -3, -9 and -13 genes and 1 promoter SNP in the 
TIMP2 gene in 208 Chinese Han MMD patients, including 
31 familial MMD patients and 224 control patients. In a 
dominant genetic model, the frequency of the MMP-3 5A/6A 
and 5A/5A genotypes was significantly lower in MMD 
patients (OR = 0.57, 95% confidence interval 0.38–0.86, 
pcorr = 0.042) than in healthy controls. Subjects with the 
5A/6A and 5A/5A genotypes had a 43% reduced risk of 
MMD compared to those with the homozygous 6A/6A 
genotype. The 6A allele frequency was higher in patients 
than in controls (85.3 vs. 78.8%; OR = 0.64, 95% convidence 
interval 0.45–0.91, p = 0.013), but this was not significant 
after Bonferroni correction (pcorr = 0.078). Significant dif-
ferences of the MMP-3 5A/6A polymorphism (rs3025058) 
were also detected between familial MMD patients and 
controls both in the dominant genetic model (OR = 0.23, 
95% confidence interval 0.08–0.68, pcorr = 0.048) and the 
additive genetic model (OR = 0.24, 95% confidence inter-
val 0.08–0.69, pcorr = 0.048). No difference in the MMP-3 
5A/6A polymorphism distribution was found among patients 
with different clinical and age characteristics. The allele 
and genotype distributions of the other 5 SNPs, including 
TIMP2 rs8179090, did not reveal any association. Thus, this 
polymorphism in the MMP-3 promoter might be associated 
with susceptibility to familial and non-familial MMD in 
the Chinese Han population [87]. Wang et al. performed an 
association study of polymorphisms of PDGFRB, MMP-
3, TIMP2, and RNF213 genes in 96 non-familial Chinese 
Han MMD patients and 96 controls. The loci rs3025058 
in MMP-3 and rs8179090 in TIMP2 were analyzed, but no 
significant association between the polymorphisms and non-
familial MMD was observed [88], whereas the association of 
rs8179090 in TIMP2 initially described by Kang et al. was 
found in Korean MMD patients [84]. Park et al. performed 
an association study focused on 6 SNPs in MMPs-2, -3, and 
-9 and TIMP2 in 107 Korean MMD patients (no familial 
cases were included) and 243 controls. A significantly higher 
frequency of TIMP2 -418 G > C (rs8179090) was found in 
MMD patients, corroborating previous results reported by 
Kang et al. [84]. The dominant (GG vs. GC + CC) geno-
type of TIMP2–418 was more frequent in patients with 
MMD. The MMP-9 Q279R (rs17576) GA + AA genotype 
showed a protective effect for MMD. The GA/CC MMP-2 
-1575(rs243866)/-1306 (rs243865) genotype was signifi-
cantly more prevalent in MMD patients [89]. Ma et al. per-
formed a case–control study to examine association between 
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MMP-3 polymorphisms and the risk of MMD, comparing 86 
Chinese Han MMD patients and 86 controls. MMP-3 6A/6A 
genotype (OR = 1.93, 95% confidence interval 1.00–3.72; 
p = 0.05) and 6A allele frequencies (OR = 1.78, 95% confi-
dence interval 1.00–3.14; p = 0.05) in the MMD group were 
significantly higher than those in the control group. Fur-
thermore, a meta-analysis was performed including two for-
mer studies that evaluated the association between MMP-3 
polymorphism and the risk of MMD [87, 88], analysing a 
total of 796 Chinese Han MMD patients. This meta-anal-
ysis revealed that one copy of the 6A allele significantly 
increases the risk of MMD (OR = 1.64, 95% confidence 
interval 1.26–2.13, p = 0.0002). Moreover, the risk of MMD 
was higher in the 6A/6A genotype than in the genotypes 
of 6A/5A and 5A/5A (OR = 1.79, 95% confidence interval 
1.32–2.42, p = 0.0002) [90]. Recently, Wang et al. published 
a meta-analysis, evaluating seven polymorphisms in 4711 
MMD patients and 8704 controls in 24 studies. This meta-
analysis showed an inverse association of TIMP2 rs8179090, 
MMP-2 rs243865 and MMP-3 rs3025058 with MMD [91]. 
Summarized, the presented studies reported associations 
between MMD and polymorphisms located in the genes or 
promoters of TIMP2, MMP-2, -3 and -9. Nevertheless, it is 
difficult to draw conclusions about the significance of these 
results and their influence in the pathophysiology of MMD 
due to conflicting results of the published studies and lack 
of reproductions.
Cytokines and Growth Factors: Vascular Endothelial Growth 
Factor (VEGF)
Several cytokines and growth factors have been associated 
with MMD. Vascular endothelial growth factor (VEGF) 
expression has been reported to be significantly increased 
in MMD patient’s dural tissue [92] and plasma VEGF 
concentrations in MMD patients were significantly higher 
than those in healthy controls [93, 94]. VEGF is crucial in 
endothelial cell proliferation, migration, survival and vas-
cular permeability during vasculogenesis and angiogen-
esis [95]. VEGF binds to tyrosine kinase cell receptors: 
VEGFR-1 (Fms-like tyrosine kinase = Flt-1), VEGFR-2 
(kinase insert domain receptor = KDR) and VEGFR-3 
(Fms-like tyrosine kinase 4 = Flt-4), with VEGFR-2 hav-
ing the strongest pro-angiogenic activity [96]. Changes in 
the corresponding gene could lead to the pathological hall-
mark 3. Park et al. conducted a case–control study to inves-
tigate whether VEGF (-2578C > A, -1154G > A, -634G > C, 
and 936C > T) and KDR (-604  T > C, 1192G > A, and 
1719 T > A) polymorphisms are associated with MMD in 
107 Korean patients and 243 healthy control subjects. No 
differences were observed in VEGF or KDR polymorphisms 
between the MMD patients and the control subjects. The 
subjects were divided into pediatric (< 18 years) and adult 
(≥ 18 years) groups, revealing that the VEGF-634CC geno-
type occurred significantly less frequently in the pediatric 
MMD group. The frequencies of the KDR polymorphisms in 
both the pediatric and adult subgroups were not significantly 
different, whereas the KDR -604C/1192A/1719 T haplotype 
significantly increased the risk of pediatric MMD. Among 
the 64 surgical patients (indirect bypass surgery), collateral 
vessel formation was evaluated after two years. Patients with 
the CC genotype of VEGF -634 had better collateral ves-
sel formation after surgery, altogether suggesting that the 
VEGF -634G allele is associated with pediatric MMD and 
poor collateral vessel formation [97]. Soluble VEGF recep-
tor (sVEGFR) -1 and -2 may play a role in the pathogenesis 
of MMD as they seem to influence postoperative collater-
alization. Patients with good collateral formation appeared 
to have lower sVEGFR-1 and sVEGFR-2 levels prior to and 
at day seven following bypass surgery when compared with 
patients with worse collateralization [98].
Cytokines and Growth Factors: Platelet‑Derived 
Growth Factor (PDGF), PDGF Receptor Beta (PDGFRβ), 
and Transforming Growth Factor beta (TGFβ)
The platelet-derived growth factor (PDGF, e.g., PDGF-
B/-BB) and the PDGF receptor beta (PDGFRβ, encoded 
by PDGFRB), as well as transforming growth factor beta 
(TGFβ, encoded by TGFB) signalling regulate endothelial 
and mural cells and the interactions of pericytes/SMC with 
endothelial cell tubes and thereby blood vessel differentia-
tion, formation and tightness [99, 100]. Alterations of the 
corresponding genes could lead to the pathological hall-
marks 3 and 4. PDGF has been shown to have an angio-
genic effect and has also been implicated in the regulation 
of the tonus of blood vessels [101]. PDGF-B induces mural 
cell fate in undifferentiated mesenchymal cells and stimu-
lates proliferation of vascular SMC. PDGF-B is secreted as 
a homodimer from the endothelium of angiogenic sprouts, 
serving as an attractant for comigrating pericytes, which 
express PDGFRβ4 [99]. In vitro studies reported a decrease 
in growth of cultured SMC derived from arteries of MMD 
patients as response to PDGF-BB, a fact explained by the 
reduced number of the PDGF receptors on these SMC [102, 
103]. MMD patients exhibited significantly higher plasma 
concentrations PDGF-BB [94], which may be explained 
as a compensative mechanism to a systemically decreased 
amount of PDGFB receptors [104]. TGFB1 is a multifunc-
tional protein associated with regulation of cell growth 
and differentiation and a potent angiogenic factor as well 
as a major modulator of the expression of connective tis-
sue genes [105]. Higher concentrations of TGFB1 were 
found in blood serum and SMC of MMD patients [105], 
pointing to a possible role in the pathophysiology of MMD. 
In 2010 and 2011, Roder et al. published the first genetic 
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studies on Caucasian MMD patients from central Europe 
(mainly Swiss and German). Their first study was based on 
the examination of 13 SNPs in or upstream of 4 genes of 
cytokines and growth factors with known abnormalities in 
MMD patients (BFGF, CRABP1, PDGFRB and TGFB1), 
comparing 40 DNA samples of MMD patients to 68 healthy 
controls. They found a significant association of two SNPs: 
rs382861 [A/C] (p = 0.0373, OR = 1.81, 95% confidence 
interval  1.03–3.17) in the promoter region of PDGFRB and 
rs1800471 [C/G] (p = 0.0345, OR = 7.65, 95% confidence 
intercal  0.97–59.95), located in the first exon of TGFB1. 
Rs1800470, also located in exon1 of TGFB1, showed ten-
dencies towards a risk allele [104]. The second study was 
based on the description of common histopathological 
changes in the vessels of MMD patients and patients with 
atherosclerotic disease. Seventeen SNPs in or adjacent to 11 
genes that had previously been described to be associated 
with atherosclerotic disease (ELN, LIMK1, CDKN2A/B, 
CXCL12, Pseudogene ENSG00000197218, PSRC-1, MTH-
FD1L, SMAD3, MIA3, PDGF-B, TIMP2) were analyzed, 
again comparing 40 DNA samples of European MMD 
patients to 68 healthy controls. Strong association of the 
SNP rs599839 [A/G] (OR = 2.17, 95% confidence inter-
val 1.17-4.05; p = 0.01) with the risk allele G located on 
chromosome 1p13.3 in the 3' UTR region of the PSRC-1 
gene and a trend towards significance for three other SNPs 
(rs8326, rs34208922, rs501120) in or adjacent to the genes 
ELN and CXCL12 were found [86]. PDGFRB and TGFB1 
have been further analyzed in different association studies 
including further ethnicities. Liu et al. performed genotyping 
of the previously described SNPs rs1800470 and rs1800471 
in 45 Japanese MMD patients and 79 healthy controls. The 
association of rs1800471 and tendency toward significance 
of rs1800470 previously described in the European cohort 
[104] could not be replicated in the Japanese cohort. Fur-
thermore, the complete first exon of TGFB1 was genotyped 
in 40 European MMD patients and 68 healthy controls, 
whereby no new disease-associated nor other genetic vari-
ations could be identified. This in turn makes a role of this 
TGFB1 exon in the pathogenesis of MMD unlikely [106]. In 
the association study of polymorphisms of PDGFRB, MMP-
3, TIMP-2 and RNF213 genes in 96 non-familial Chinese 
Han MMD patients and 96 controls performed by Wang 
et al., the SNP rs3828610 in PDGFRB was analyzed, show-
ing no significant association to non-familial MMD [88].
Several other SNPs and genes
Several other SNPs and genes have been associated with 
MMD, for example the frequency of the CT + CC genotype 
in the SNP rs11614913 in miR-196a2 was significantly 
higher in Korean MMD patients, which suggests that miR-
196a2 may play a role in the pathogenesis of MMD [107]. 
MMD has been associated with autoimmune disease, e.g., 
Graves disease and systemic lupus erythematosus [4] and 
Kawasaki disease [108]. Shen et al. analyzed patients’ DNA 
of 48 Chinese pediatric MMD patients and 50 healthy con-
trols for five SNPs in B lymphoid tyrosine kinase, CD40 
and coatomer protein complex beta-2 subunit, which had 
been associated with Kawasaki disease before. Two SNPs 
of CD40 were associated with MMD: the polymorphisms 
rs4813003 major allele CC and rs1535045 minor allele TT 
were significantly associated with MMD, providing evidence 
for autoimmune dysfunction in MMD patients [109]. Yang 
et al. reported that the SNP (c.13185159G > T, p.V265L) 
on PHACTR1 was highly associated with the disease pro-
gression of MMD in Chinese MMD patients. Silencing 
of PHACTR1 reduced survival of human coronary artery 
endothelial cells [110]. The most highly enriched variant 
in 10 of 68 Caucasian MMD patients (14.7%) in a study 
by Shoemaker et al. was rs16837497 (ZXDC, p.P562L, 
involved in MHC Class II activation). This variant has a 
frequency of 4% in the Caucasian population. Furthermore, 
collapsing variant methodology ranked OBSCN (involved 
in myofibrillogenesis) as most enriched in Caucasian and 
non-RNF213 founder mutation cases, revealing alternative 
candidate genes and thus confirming the multiethnic genetic 
landscape of MMD [111]. To further identify genes involved 
in the pathogenesis of MMD, exome sequencing was pur-
sued in 197 unrelated Caucasian patients (172 bilateral, 24 
unilateral, and 1 unknown) and 125 relatives (21 affected 
and 104 clinically healthy), including a total of 39 trios. 39 
genes harbouring rare de novo variants were identified in 26 
MMA trios (2 trios had 3 de novo variants, 12 trios had 2 de 
novo variants, 12 trios had 1 de novo variant). Three of these 
variants were in RNF213 and one was a variant of unknown 
significance in NF1. In four MMA patients, de novo variants 
in three genes, CHD4, CNOT3 and SETD5, were identified, 
previously found to harbour pathogenic de novo variants 
in children with developmental disorders [112]. Peng et al. 
investigated gene dysregulation in peripheral blood of twelve 
Chinese MMD patients and compared it with other vascu-
lar disorders. A total of 533 differentially expressed genes 
(DEGs) were identified for MMD. Up-regulated genes were 
mainly involved in ECM organization, whereas downregu-
lated genes were primarily associated with inflammatory 
and immune responses [113]. Rare de novo copy number 
variation (CNV) screening was performed by Aloui et al. 
in 13 MMD trios using whole exome sequencing (WES) 
read depth data and whole genome high density SNP array 
data. WES and SNP array data from an additional cohort of 
115 unrelated MMD patients were used to search for recur-
rence of CNVs. Two de novo CNVs were identified in two 
unrelated probands. One of these CNVs, located on Xq28, 
was detected in two additional families. The critical region 
contains five genes, including MAMLD1, a major NOTCH 
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coactivator [114]. Recently, DIAPH1 (mammalian diapha-
nous-1) has been described as a novel MMD risk gene in 
non-East Asian individuals with sporadic MMD by impair-
ing vascular cell actin remodelling [115].
RNF213
First Description as Susceptibility Gene for MMD
In 2011, the first GWAS on MMD revealed an association 
with a new primary susceptibility gene for MMD, RNF213, 
also known as mysterin, encoding the 591-kDa protein “ring 
finger protein 213” with two AAA + modules (ATPases 
associated with diverse cellular activities) and a single RING 
finger ubiquitin ligase domain [116]. A GWAS of 785.720 
SNPs was performed, comparing 72 Japanese MMD patients 
including 8 familial MMD patients with 45 control subjects. 
A strong association of chromosome 17q25-ter with MMD 
risk was shown and further confirmed by a locus-specific 
association study using 384 SNPs in the 17q25-ter region. 
Mutational analysis of RNF213 (located on chromosome 
17q25) revealed a founder variant, p.R4859K (single base 
substitution c.14576G > A in exon 60 of RNF213) in 95% 
of MMD families, 73% of non-familial MMD cases and 
1.4% of controls. The carrier frequency of p.R4859K in 
Japan was assumed to be 1/72. This variant significantly 
increased the risk of MMD (OR 190.8). The p.R4859K vari-
ant was not present among Caucasian patients or controls 
[64] nor in Korean patients [117]. In the same year, Liu 
et al. also provided evidence on the involvement of RNF213 
in genetic susceptibility to MMD. Genome-wide linkage 
analysis in 8 three-generation Japanese families with MMD 
confirmed significant linkage to 17q25.3. Exome analysis 
revealed the missense variant p.R4810K (single base sub-
stitution c.14429G > A, rs112735431) in RNF213 in the 
1.5-Mb locus of 8 index cases in these families. Sequenc-
ing RNF213 in 42 further patients confirmed p.R4810K and 
revealed it to be the only unregistered variant. Genotyping 
39 SNPs around RNF213 revealed a founder haplotype 
transmitted in 42 families. A further conducted case–con-
trol study demonstrated strong association of p.R4810K 
with MMD in East Asian populations (251 cases and 707 
controls) with an OR of 111.8. The population attributable 
riRNF213 Variants in Caucasianssks and OR in the Japa-
nese (145/161 = 90%; 339.94) and Korean (30/38 = 79%; 
135.63) populations were higher than those in the Chinese 
population (12/52 = 23%; 14.70). The p.R4810K vari-
ant was not present among Caucasian patients or controls 
[65]. It is important to note that there are several transcripts 
of the RNF213 gene: NM_001256071.3:c.14429G > A; 
p.R4810K and XM_005257545.1:c.14576G > A; p.R4859K 
both correspond to the SNP rs112735431. It is therefore the 
same variant that has been described in these two initial 
publications.
Distribution of the Founder Variant p.R4810K in East 
Asia
Association of p.R4810K was further confirmed in Japanese, 
Chinese and Korean patients in large-scale case–control 
studies [117–124]. The carrier rates of p.R4810K in MMD 
patients were greatly discrepant in different populations. In 
Japan and Korea, the distribution of the p.R4810K variant 
was similar with a frequency of 67.4–90% and a frequency 
of homozygous carriers of 5.3–7.9% [65, 117, 118, 125, 
126]. The distribution of the p.R4810K variant in China is 
quite different from Japan and Korea with much lower rates 
of homozygous and heterozygous carriers than wild type 
carriers. A large-scale case–control study in Chinese Han 
patients reported p.R4810K variant in 22/170 patients (13%) 
including 21 heterozygotes and a single familial homozygote 
[127]. The lower carrier rates in Chinese patients were fur-
ther confirmed by Wang et al. with frequencies of 0.5% for 
homozygous, 22.4% for heterozygous and 76.1% for wild 
type carriers [122]. Liao et al. conducted a meta-analysis, 
again confirming association of RNF213 p.R4810K, which 
significantly increased familial MMD risk in the Japanese, 
Korean and Chinese population (dominant model ORs 
1802.44, 512.42, and 1109.02), with 5–36 times larger effect 
sizes than that for sporadic cases (dominant model ORs 
134.35, 99.82, and 30.52). The effect sizes of p.R4810K to 
sporadic MMD were 3–4 times larger in Japan and Korea 
than those in China [128]. The RNF213 p.R4810K variant 
segregates with MMD in Asian families [65]. In East Asian 
MMD patients negative for p.R4810K, other rare RNF213 
variants have been described and conferred susceptibility to 
MMD (see below). Approximately 20% of Japanese MMD 
patients do not harbour susceptibility variants of RNF213, 
indicating the presence of other susceptibility genes for 
MMD [119].
RNF213 Variants in Caucasians
Neither the p.R4810K nor the p.R4859K variant have been 
detected in Caucasian patients, suggesting that these vari-
ants are Asian-specific RNF213 founder variants and may 
contribute to the high incidence of MMD in East Asia [129]. 
No predominant susceptibility variants have been identi-
fied in Caucasian MMD patients so far [130]. Several rare 
RNF213 variants distinct from p.R4810K and p.R4859K 
have been reported in Caucasian MMD patients with no fur-
ther evidence of association in large patient cohorts [54, 65, 
129, 131–134], such as p.D4013N, p.R4019C, p.E4042K, 
p.V4146A, and p.W4677L in Slovakian and Czech MMD 
patients [135]. Guey et al. investigated whether rare RNF213 
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variants are associated with increased risk of MMD and 
provided significant evidence for a positive association of 
rare RNF213 missense variants and MMD in European 
patients with an even stronger association in early onset and/
or familial cases. Interestingly, these rare variants found in 
the Caucasian MMD patients are significantly grouped in a 
C-terminal region of RNF213 that includes the RING fin-
ger domain [136]. The named studies confirmed RNF213 
as a causative gene for MMD not only in Asian but also in 
Caucasian patients.
Penetrance and Pathophysiological Relevance
A meta-analysis of five previously published studies [64, 
65, 118, 127, 137], including 421 (Chinese/East Asian/
Caucasian) patients and 1214 controls for the p.R4810K 
polymorphism and 398 Japanese patients and 765 controls 
for the p.R4859K polymorphism confirmed strong associa-
tions between the p.R4810K polymorphism of the RNF213 
gene and MMD (pooled OR 157.53 vs. 92.03) [138]. A fur-
ther meta-analysis confirmed association of rs112735431 
(= variant p.R4810K) polymorphism with MMD [139]. In 
conclusion, the R4810K/R4859K variant is found in East 
Asian patients and distinct other variants have been observed 
in Asians and Caucasians [54, 64, 65, 88, 111, 119, 120, 
127–129, 131–136, 140]. GnomAD V2 (the Genome Aggre-
gation Database of healthy individuals, aggregating 15.708 
whole genomes and 125.748 exomes) shows a global allele 
frequency of 0.0002 for the rs112735431 allele (= variant 
p.R4810K); this allele frequency reaches a maximum of 
0.01 in Korean individuals. In above mentioned studies, 
p.R4810K was observed in 1–2% of the general East Asian 
population [65, 141]: p.R4810K was detected at allele fre-
quencies of 0.43%, 1.36%, and 1.36% in the Chinese (with 
heterogeneous distribution), Japanese and Korean popula-
tions, respectively. Frequencies of 1.00% in 4 of 11 investi-
gated locations in China and frequencies of 1.00–1.72% in 
all investigated locations in Japan and Korea were reported. 
The estimated total numbers of carriers were 11.41 mil-
lion for the Chinese, 3.39 million for the Japanese and 1.36 
million for the Korean population. The number of patients 
with MMD, which was estimated at approximately 1 per 
300 carriers of p.R4810K, was considered to be 53.800 in 
East Asian populations (38.000 in the Chinese, 4.500 in 
the Korean and 11.300 in the Japanese population) [141]. 
It is now very clear that this variant is associated with and 
substantially increases the susceptibility to MMD, but the 
penetrance of this variant is low as numerous carriers are 
unaffected and is estimated to be close to 1/150–300 (based 
on the respective frequencies of this allele in MMD patients 
versus the healthy Japanese population). Thus, other triggers 
are needed to develop the disease, such as environmental 
factors. Therefore, the reported RNF213 variants should be 
considered as susceptibility variants rather than a causing 
variants for MMD. RNF213 is a large gene (encoding 5207 
amino acids) and harbours a number of variants in healthy 
subjects as well as in patients and false attribution of patho-
genicity can have severe consequences for patients, resulting 
in incorrect prognostic, therapeutic or reproductive advice 
[142, 143].
Genotype–Phenotype Correlation
After describing RNF213 as a new susceptibility gene, fur-
ther studies have addressed the question whether different 
doses of RNF213 variants differ in the clinical phenotype 
of MMD. Besides the mentioned differences in the distribu-
tion of the variants, there is also a difference in the clini-
cal phenotype between East Asian countries. In Japan and 
Korea, p.R4810K homozygous carriers showed a similar 
and more severe phenotype. Compared with heterozygotes 
in a Japanese MMD cohort, c.14576G > A (= p.R4859K) 
homozygotes had a significantly earlier age at onset. 60% 
of homozygotes were diagnosed before the age of four and 
all had infarctions as the first symptom. Infarctions at initial 
presentation and involvement of posterior cerebral arteries 
(PCA) were significantly more frequent in homozygotes than 
in heterozygotes and wild types, both known as poor prog-
nostic factors in MMD. The incidence rate for homozygotes 
of the c.14576G > A variant was calculated to be > 78%. 
Thus the homozygous c.14576G > A variant was suggested 
to be a possible genetic biomarker for predicting a severe 
form of MMD [118]. These findings were further confirmed 
in Japanese MMD siblings. The c.14576G > A homozygous 
brother showed an early onset age and rapid disease pro-
gression with significant neurological deficits and a severe 
distribution of vasculopathy, whereas the heterozygous sister 
showed a late onset age and mild clinical course with a lim-
ited distribution of vasculopathy. Therefore, different doses 
of this RNF213 variant seem to influence the clinical pheno-
type, even in individuals with a similar genetic background 
[144]. Another study involving 165 Korean MMD patients 
confirmed dosage dependence of clinical presentation as 
the homozygous state of the c.14429G > A (p.R4810K) 
allele was highly associated with early-onset MMD (age at 
onset < 5 years), severe symptomatic manifestations such as 
cerebral infarction at diagnosis and cognitive impairment 
in long-term outcome [117]. There are different, partially 
contradictory reports on the angiographic findings in Japa-
nese and Korean patients. Miyatake et al. reported that PCA 
involvement in p.R4180K homozygous patients and bilateral 
vasculopathy in p.R4810K homozygous and heterozygous 
patients was significantly more frequent than in the other 
genotypes in Japanese patients [118]. Nevertheless, Kim EH 
et al. reported that there was no difference in Suzuki stage, 
PCA involvement or bilateral vasculopathy between the 
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genotypes in Korean patients [117], whereas Kim WH et al. 
reported that leptomeningeal collateral flow from posterior 
to anterior circulation was more frequent in the RNF213-
negative group than in the RNF213-positive group and PCA 
territorial involvement was more frequently observed in 
RNF213-positive than in RNF213-negative Korean patients 
[145]. Regarding long-term cohorts, Nomura et al. followed 
phenotypic parameters (recurrent stroke after initial revascu-
larization and final modified Rankin Scale) over a long-term 
period after direct or combined revascularization in Japanese 
patients. Over a median follow-up period of 100 months, 
there were no significant differences among the genotypes. 
The study confirmed that the p.R4810K variant of RNF213 
influences the phenotype at onset, but there were no signifi-
cant differences between the genotypes after revasculariza-
tion. The frequency of recurrent stroke was low, even in 
the homozygous patients. Thus, direct or combined bypass 
surgery is suggested to be an effective treatment for all geno-
types, including homozygous, heterozygous and wild type 
and the RNF213 genotype may not strongly influence the 
long-term clinical manifestations or poor prognosis in Japa-
nese patients with MMD [125].
In comparison to Japanese and Korean patients, Wang 
et al. reported that the p.R4810K homozygous and heterozy-
gous variants were also associated with early age at onset 
in Chinese patients, but no significant difference was found 
in the severity of initial symptoms between patients carry-
ing the RNF213 p.R4810K variant and non-carriers. Unlike 
homozygous Japanese patients, who displayed infarction as 
the most common presentation, most (66.7%) of the Chi-
nese p.R4810K homozygous carriers initially presented with 
TIA. This finding was contrary to the findings in Japanese 
and Korean patients and was not suggestive of a correla-
tion between p.R4810K homozygous genotype and severe 
clinical manifestation in Chinese patients [122]. The allele 
frequency of p.R4810K was significantly higher in patients 
presenting with ischemia than in patients presenting with 
hemorrhage (OR = 5.4) [127]. According to multivariate cox 
regression analysis, the p.R4810K variant was not related 
to recurrent stroke or the neurological status. Therefore, 
similar to Japanese MMD patients, the p.R4810K variant 
may not be associated with long-term clinical outcome in 
Chinese patients. Compared to p.R4810K wild-type patients, 
heterozygous and homozygotes patients had a lower rate of 
recurrent stroke and better clinical outcome after early medi-
cal and surgical interventions [146]. Thus, surgical revas-
cularization is suggested to be an effective treatment for 
p.R4810K heterozygous and homozygous  Chinese patients. 
Angiographically, some heterozygous patients with MMD 
were more susceptible to PCA involvement than patients 
carrying wild-type alleles [122]. When comparing collat-
eral vessels (lenticulostriate vs. thalamic vs. choroidal) in 
hemorrhagic hemispheres in heterozygous and wild-type 
p.R4810K variant patients, lenticulostriate anastomoses 
were found more frequently in heterozygous patients, thus 
lenticulostriate anastomoses might be associated with the 
p.R4810K variant in Chinese patients [147]. Compared to 
the wild-type p.R4810K variant, Chinese patients carrying 
the heterozygous p.R4810K variant showed better postop-
erative collateral formation after direct/indirect/combined 
bypass surgery [148].
Besides this RNF213 p.R4810K dose effect, mutations 
in different sites of RNF213 may have various effects on 
blood vessels. The RNF213 p.R4810K mutation may be 
the main cause of MMD intracranial artery stenosis and 
is more related to the MMD ischemic phenotype, whereas 
the rarer RNF213 p.A4399T mutation is more related to 
the MMD hemorrhagic phenotype [127, 149]. Apart from 
MMD, RNF213 variants have also been described in other 
cerebrovascular diseases such as intracranial aneurysms and 
intracranial major artery stenosis/occlusion and different 
mutation sites may be involved in various cerebrovascular 
diseases as mutations in the ATPase domain are predomi-
nantly related to intracranial aneurysms and mutations in 
the RING finger domain are all related to MMD (c.11990 
G > A, c.12020 C > G, c.12037 G > A, and c.12055 C > T) 
[127, 129, 135, 149, 150]. In other diseases than MMD, 
RNF213 variants also lead to a more severe clinical course, 
e.g., R4810K carrier status was independently associated 
with recurrent cerebrovascular events in patients with intrac-
ranial atherosclerosis [151] and the p.R4810K variant was 
associated with poor clinical outcomes in patients suffering 
idiopathic pulmonary arterial hypertension [152]. De novo 
variants in RNF213 lead to early-onset and severe MMD 
with involvement of the abdominal aorta and renal, iliac, 
and femoral arteries. These variants are located in two sites: 
the first region is in the RING domain and the second region 
is a highly conserved region that is located 35 amino acids 
downstream from the RING domain. These de novo variants 
all disrupt highly conserved amino acids and thus lead to 
severe early-onset MMD [134]. In summary, dosage of the 
RNF213 p.R4810K variant appears to influence the clini-
cal phenotype and postoperative outcome but not the long-
term prognosis of MMD patients with differences between 
Japanese/Korean and Chinese patients, which is why it is 
suggested that RNF213 mutational analysis should form 
part of the diagnostic workup for MMD in clinical practice. 
The genotype–phenotype correlation of rare RNF213 vari-
ants other than p.R4810K has not been well studied in large 
patient cohorts in neither Asian nor Caucasian patients but 
different mutation sites and rare de novo variants lead to 
varying MMD phenotypes and different mutation sites may 
be involved in various cerebrovascular diseases.
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Experimental Research
After RNF213 has been described as a susceptibility gene 
for MMD, several groups conducted experimental research 
on the possible role of RNF213 in the pathophysiology of 
MMD. RNF213 is expressed throughout the body in humans 
and mice with the highest expression in immune tissues [64, 
65]. RNF213 encodes the 591-kDa protein “ring finger pro-
tein 213” with two AAA + modules (ATPases associated 
with diverse cellular activities) and a single RING finger 
ubiquitin ligase domain. The RNF213 protein shows a dif-
fuse distribution in the cytosol and is partly associated with 
undetermined intracellular structures. RNF213 has the abil-
ity to form toroidal oligomers and to hydrolyze ATP [116], 
whereas its function and link to MMD still remains elusive. 
It remains unclear whether p.R4810K leads to gain or loss 
of function of RNF213. The p.R4810K variant did not affect 
the transcription level, the ubiquitin ligase activity, the intra-
cellular distribution or the stability of the protein. Knock-
down of RNF213 in zebrafish caused irregular wall forma-
tion in trunk arteries and abnormal sprouting vessels in the 
head region [65]. Sonobe et al. generated RNF213-deficient 
mice (RNF213-/-) which did not develop MMD: no signifi-
cant difference was observed in MRI-angiography findings, 
the anatomy of the circle of Willis or vascular wall thick-
ness. However, the intimal and medial layers of the common 
carotid artery (proximal to bifurcation) were significantly 
thinner after ligation of the same in RNF213-/- mice, thus 
RNF213 abnormality may affect vascular wall remodelling 
under ischemic conditions [153]. Transient middle cerebral 
artery occlusion (tMCAO) in RNF213-/- mice compared 
to wild-type littermates did not show any cerebrovascular 
differences [154]. Thereafter, the same group generated 
RNF213-knock-in mice, resulting in a mouse featuring 
RNF213 p. R4828K, corresponding to p.R4859K in MMD 
patients. Again, RNF213-knock-in mice did not sponta-
neously develop MMD [155]. Morimoto et al. published 
results of bilateral common carotid artery stenosis surgery 
in RNF213-/- mice and vascular endothelial cell-specific 
RNF213 mutant (human p.R4810K orthologue) transgenic 
(EC-Tg) mice, revealing a significantly stronger reduction of 
CBF in the RNF213-/- mice than in wild-type mice [156]. 
Induced pluripotent stem cells (iPSCs) have been generated 
by several research groups [157–163]. Angiogenic activities 
of iPSC-derived vascular endothelial cells (iPSECs) from 
carriers and patients were lower than those of wild-type 
donors [157]. Angiogenesis was significantly impaired in 
MMD iPSECs regardless of the presence of angiogenic fac-
tors such as VEGF, whereas endothelial proliferation was 
not attenuated [158]. Although there is increasing evidence 
of reduced angiogenesis by RNF213 alterations, it remains 
difficult to interpret how reduced angiogenesis leads to an 
abnormal vascular network in MMD patients. In further 
cell-culture based experiments, knockdown of RNF213 in 
cultured endothelial cells led to the decrease of endogenous 
expression of cell cycle-promoting genes and less prolif-
erative and angiogenic profiles [164]. The ratio of regula-
tory T cells after the administration of muramyl dipeptide 
(MDP)-Lys (L18) was significantly decreased in RNF213-
deficient mice [165] and RNF213 was up-regulated by inter-
feron beta [166], both suggesting a further involvement of 
RNF213 in the regulation of the immune system. RNF213 
down-regulated expressions of MMPs in endothelial cells 
and thus controls the expressions of MMPs as an upstream 
regulator [164] and MMP-9 expression was significantly 
higher in RNF213-/- mice than in wild-type mice after com-
mon carotid artery ligation [167]. Through these effects on 
MMPs, RNF213 might play a potential role in the patho-
genesis of the pathological hallmarks 1–3. Experimental 
research on RNF213-dependent effects inconsistently shows 
vascular changes without establishment of a representative 
MMD animal model. Cell culture experiments, including 
induced pluripotent stem cell derived vascular endothe-
lial cells, are a promising approach to investigate the gap 
between mutations in candidate genes such as RNF213 and 
the development of MMD.
Conclusion
To date, the exact pathophysiology of Moyamoya Dis-
ease has not been conclusively clarified. By evaluating the 
disease epidemiology with an early age of onset, famil-
ial cases and significant ethnic differences in the incidence 
and prevalence, a focus was put on the genetic aspects early 
on. The disease is characterized by certain pathological hall-
marks, e.g., affection of the vessel wall and smooth muscle 
cells, increased angiogenic activity and altered vascular 
plasticity andfragility. Given these pathological hallmarks, a 
heterogeneous variety of genes could possibly be involved in 
the development of MMD. Over the last decades of genetic 
research, revolutionary techniques have been developed and 
applied, from genetic linkage studies and association stud-
ies to DNA sequencing including whole genome sequenc-
ing. These techniques have continuously yielded new results 
regarding the genetic basis of MMD, which in turn partially 
represent the pathological hallmarks. Such as association 
studies that revealed association to alterations in the genes 
of MMP, VEGF, PDGFRB, and TGFB, all substantially 
involved in the normal functioning of vessels. The HLA sys-
tem has been studied in Asian and European MMD patients 
and several associations have been described. Linkage analy-
ses verified linkage to the chromosome 17q25 and sequenc-
ing of genes encoded in this area revealed a new candidate 
gene, RNF213. The RNF213 founder variant p.R4810K 
is frequently found in East Asian (Japanese, Korean and 
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Chinese) MMD patients and dramatically increases the 
risk of and susceptibility to MMD with a dose-dependent 
effect on clinical phenotype severity. Many non-p.R4810K 
variants of RNF213 and rare variants of other genes have 
been identified in MMD patients worldwide, but p.R4810K 
was found to be absent in non-Asian patients, suggesting 
that this variant is Asian-specific and may contribute to the 
high incidence of MMD in East Asia. Proof of causality 
and pathogenicity of these variants is still pending. RNF213 
p.R4810K increases the susceptibility to MMD, however, 
it was also observed in 1–2% of the general East Asian 
population, indicating a low penetrance as many carriers 
are unaffected. Therefore, it is strongly suggested that in 
addition to p.R4810K, environmental factors play a critical 
role in MMD pathophysiology. Experimental research on 
RNF213-dependent effects inconsistently shows vascular 
changes without establishment of a representative MMD 
animal model. Cell culture experiments, including stem cell 
derived vascular endothelial cells, are a promising approach 
to investigate the gap between variants in candidate genes 
and the development of MMD. RNF213 is a large gene that 
harbours a number of variants in healthy subjects as well 
as in MMD patients and false attribution of pathogenicity 
can lead to severe consequences for patients, resulting in 
incorrect prognostic, therapeutic or reproductive advice. 
Therefore, by now RNF213 variants should be considered 
as susceptibility variants rather than causing variants for 
MMD. Future studies have to identify how different genetic 
pathways and environmental factors interact withRNF213 in 
the pathophysiology of MMD.
Author Contribution Conceptualization: R.M. and P.V.; formal analy-
sis: all authors; writing—original draft preparation: R.M. and P.V., 
writing—review and editing: M.G., H.G., A.B., E.T-L., M.A.M, S.M.; 
supervision: P.V. All authors have read and agreed to the published 
version of the manuscript.
Data Availability The authors provide data transparency.
Declarations 
Ethics Approval This article does not contain any studies with human 
participants or animals performed by any of the authors.
Conflict of Interest The authors declare no competing interests.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article's Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article's Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http:// creat iveco mmons. org/ licen ses/ by/4. 0/.
References
 1. Takeuchi K, Shimizu K. Hypoplasia of the bilateral internal 
carotid arteries. Brain Nerve (Tokyo). 1957;9:37–43.
 2. Suzuki J, Takaku A. Cerebrovascular ‘moyamoya’ disease. Dis-
ease showing abnormal net-like vessels in base of brain. Arch 
Neurol. 1969;20:288–99.
 3. Tinelli F et al. Vascular remodeling in moyamoya angiopathy: 
from peripheral blood mononuclear cells to endothelial cells. Int 
J Mol Sci. 2020;21(16). https:// doi. org/ 10. 3390/ ijms2 11657 63.
 4. Chen J-B, Liu Y, Zhou L-X, Sun H, He M, You C. Increased 
prevalence of autoimmune disease in patients with unilat-
eral compared with bilateral moyamoya disease. J Neurosurg. 
2016;124(5):1215–20. https:// doi. org/ 10. 3171/ 2015.4. JNS14 
2936.
 5. Budişteanu M, et al. Neurofibromatosis type 1 associated with 
moyamoya syndrome. Case report and review of the literature. 
Rom J Morphol Embryol. 2019;60(2):713–6.
 6. Scott RM, Smith ER. Moyamoya disease and moyamoya syn-
drome. N Engl J Med. 2009;360(12):1226–37. https:// doi. org/ 
10. 1056/ NEJMr a0804 622.
 7. Spengos K, Kosmaidou-Aravidou Z, Tsivgoulis G, Vassilo-
poulou S, Grigori-Kostaraki P, Zis V. Moyamoya syndrome 
in a Caucasian woman with Turner’s syndrome. Eur J Neurol. 
2006;13(10):e7–8. https:// doi. org/ 10. 1111/j. 1468- 1331. 2006. 
01417.x.
 8. Farooq S, Testai FD. Neurologic complications of sickle cell 
disease. Curr Neurol Neurosci Rep. 2019;19(4):17. https:// doi. 
org/ 10. 1007/ s11910- 019- 0932-0.
 9. Huang S, Guo Z-N, Shi M, Yang Y, Rao M. Etiology and patho-
genesis of Moyamoya Disease: an update on disease prevalence. 
Int J Stroke. 2017;12(3):246–53. https:// doi. org/ 10. 1177/ 17474 
93017 694393.
 10. Baba T, Houkin K, Kuroda S. Novel epidemiological fea-
tures of moyamoya disease. J Neurol Neurosurg Psychiatry. 
2008;79(8):900–4. https:// doi. org/ 10. 1136/ jnnp. 2007. 130666.
 11. Miao W, et al. Epidemiological and clinical features of Moy-
amoya disease in Nanjing, China. Clin Neurol Neurosurg. 
2010;112(3):199–203. https:// doi. org/ 10. 1016/j. cline uro. 2009. 
11. 009.
 12. Ahn IM, Park D-H, Hann HJ, Kim KH, Kim HJ, Ahn HS. Inci-
dence, prevalence, and survival of moyamoya disease in Korea: a 
nationwide, population-based study. Stroke. 2014;45(4):1090–5. 
https:// doi. org/ 10. 1161/ STROK EAHA. 113. 004273.
 13. Kleinloog R, Regli L, Rinkel GJE, Klijn CJM. Regional dif-
ferences in incidence and patient characteristics of moyamoya 
disease: a systematic review. J Neurol Neurosurg Psychiatry. 
2012;83(5):531–6. https:// doi. org/ 10. 1136/ jnnp- 2011- 301387.
 14. Wetjen NM, Garell PC, Stence NV, Loftus CM. Moyamoya 
disease in the midwestern United States. Neurosurg Focus. 
1998;5(5):e1. https:// doi. org/ 10. 3171/ foc. 1998.5. 5.4.
 15. Graham JF, Matoba A. A survey of moyamoya disease in Hawaii. 
Clin Neurol Neurosurg. 1997;99(Suppl 2):S31–5. https:// doi. org/ 
10. 1016/ s0303- 8467(97) 00037-1.
 16. Uchino K, Johnston SC, Becker KJ, Tirschwell DL. Moy-
amoya disease in Washington State and California. Neurology. 
2005;65(6):956–8. https:// doi. org/ 10. 1212/ 01. wnl. 00001 76066. 
33797. 82.
Translational Stroke Research 
1 3
 17. Birkeland P, Lauritsen J. Incidence of moyamoya disease in Den-
mark: a population-based register study. Acta Neurochir Suppl. 
2018;129:91–3. https:// doi. org/ 10. 1007/ 978-3- 319- 73739-3_ 13.
 18. Hever P, Alamri A, Tolias C. Moyamoya angiopathy - is there a 
Western phenotype? Br J Neurosurg. 2015;29(6):765–71. https:// 
doi. org/ 10. 3109/ 02688 697. 2015. 10969 02.
 19. Acker G, Goerdes S, Schneider UC, Schmiedek P, Czabanka M, 
Vajkoczy P. Distinct clinical and radiographic characteristics of 
moyamoya disease amongst European Caucasians. Eur J Neurol. 
2015;22(6):1012–7. https:// doi. org/ 10. 1111/ ene. 12702.
 20. Han DH, et al. A co-operative study: clinical characteristics of 
334 Korean patients with moyamoya disease treated at neuro-
surgical institutes (1976–1994). the Korean Society for Cer-
ebrovascular Disease. Acta Neurochir. 2000;142(11):1263–4. 
https:// doi. org/ 10. 1007/ s0070 10070 024.
 21. Hallemeier CL, et al. Clinical features and outcome in North 
American adults with moyamoya phenomenon. Stroke. 
2006;37(6):1490–6. https:// doi. org/ 10. 1161/ 01. STR. 00002 
21787. 70503. ca.
 22. Lee S, Rivkin MJ, Kirton A, deVeber G, Elbers J. Moyamoya 
disease in children: results from the international pediatric 
stroke study. J Child Neurol. 2017;32(11):924–9. https:// doi. 
org/ 10. 1177/ 08830 73817 718730.
 23. Seol HJ, Wang K-C, Kim S-K, Hwang Y-S, Kim KJ, Cho 
B-K. Headache in pediatric moyamoya disease: review of 204 
consecutive cases. J Neurosurg. 2005;103(5 Suppl):439–42. 
https:// doi. org/ 10. 3171/ ped. 2005. 103.5. 0439.
 24. Kraemer M, et al. Movement symptoms in European Moy-
amoya angiopathy - first systematic questionnaire study. Clin 
Neurol Neurosurg. 2017;152:52–6. https:// doi. org/ 10. 1016/j. 
cline uro. 2016. 11. 017.
 25. Chang S, Steinberg G. Surgical management of moyamoya 
disease. Contemp Neurosurg. 2000;22:1–9.
 26. Czabanka M, et al. Proposal for a new grading of Moyamoya 
disease in adult patients. Cerebrovasc Dis (Basel, Switzerland). 
2011;32(1):41–50. https:// doi. org/ 10. 1159/ 00032 6077.
 27. “Guidelines for diagnosis and treatment of moyamoya disease 
(spontaneous occlusion of the circle of Willis).,” Neurol Med 
Chir. 2012;52(5):245–66. https:// doi. org/ 10. 2176/ nmc. 52. 245.
 28. Czabanka M, et al. Grading of moyamoya disease allows strati-
fication for postoperative ischemia in bilateral revasculariza-
tion surgery. Acta Neurochir. 2016;158(10):1895–900. https:// 
doi. org/ 10. 1007/ s00701- 016- 2941-y.
 29. Acker G, Fekonja L, Vajkoczy P. Surgical management of Moy-
amoya disease. Stroke. 2018;49(2):476–82. https:// doi. org/ 10. 
1161/ STROK EAHA. 117. 018563.
 30. Hori S, Acker G, Vajkoczy P. Radial artery grafts as rescue 
strategy for patients with Moyamoya disease for whom conven-
tional revascularization failed. World Neurosurg. 2016;85:77–
84. https:// doi. org/ 10. 1016/j. wneu. 2015. 08. 037.
 31. Teo M, Johnson J, Steinberg GK. Strategies for and outcome 
of repeat revascularization surgery for Moyamoya disease: an 
American institutional series. Neurosurgery. 2017;81(5):852–
9. https:// doi. org/ 10. 1093/ neuros/ nyx122.
 32. Patel NN, Mangano FT, Klimo PJ. Indirect revascularization 
techniques for treating moyamoya disease. Neurosurg Clin N 
Am. 2010;21(3):553–63. https:// doi. org/ 10. 1016/j. nec. 2010. 
03. 008.
 33. Kuroda S, Houkin K. Moyamoya disease: current concepts 
and future perspectives. Lancet Neurol. 2008;7(11):1056–66. 
https:// doi. org/ 10. 1016/ S1474- 4422(08) 70240-0.
 34. Fukui M, Kono S, Sueishi K, Ikezaki K. Moyamoya disease. 
Neuropathology. 2000;20(Suppl):S61–4. https:// doi. org/ 10. 
1046/j. 1440- 1789. 2000. 00300.x.
 35. Takagi Y, Kikuta K, Nozaki K, Hashimoto N. Histological 
features of middle cerebral arteries from patients treated for 
Moyamoya disease. Neurol Med Chir. 2007;47(1):1–4. https:// 
doi. org/ 10. 2176/ nmc. 47.1.
 36. Bersano A, et al. Research progresses in understanding the 
pathophysiology of Moyamoya disease. Cerebrovasc Dis 
(Basel, Switzerland). 2016;41(3–4):105–18. https:// doi. org/ 
10. 1159/ 00044 2298.
 37. Bedini G, et al. Vasculogenic and Angiogenic Pathways in 
Moyamoya Disease. Curr Med Chem. 2016;23(4):315–45. 
https:// doi. org/ 10. 2174/ 09298 67323 04160 20418 1543.
 38. Czabanka M, Peña-Tapia P, Schubert GA, Woitzik J, Vajkoczy 
P, Schmiedek P. Characterization of cortical microvasculariza-
tion in adult moyamoya disease. Stroke. 2008;39(6):1703–9. 
https:// doi. org/ 10. 1161/ STROK EAHA. 107. 501759.
 39. Czabanka M, et al. “Collateralization and ischemia in hemo-
dynamic cerebrovascular insufficiency.” Acta neurochirurgica. 
2014;156(11):2051–8; discussion 2058, Nov. 2014. https:// doi. 
org/ 10. 1007/ s00701- 014- 2227-1.
 40. Narducci A, Yasuyuki K, Onken J, Blecharz K, Vajkoczy P. 
In vivo demonstration of blood-brain barrier impairment in Moy-
amoya disease. Acta Neurochir. 2019;161(2):371–8. https:// doi. 
org/ 10. 1007/ s00701- 019- 03811-w.
 41. Blecharz KG, et al. Autocrine release of angiopoietin-2 medi-
ates cerebrovascular disintegration in Moyamoya disease. J 
Cereb Blood Flow Metab. 2017;37(4):1527–39. https:// doi. org/ 
10. 1177/ 02716 78X16 658301.
 42. Lim M, Cheshier S, Steinberg GK. New vessel formation in the 
central nervous system during tumor growth, vascular malforma-
tions, and Moyamoya. Curr Neurovasc Res. 2006;3(3):237–45. 
https:// doi. org/ 10. 2174/ 15672 02067 78018 730.
 43. Yamashita M, Tanaka K, Matsuo T, Yokoyama K, Fujii 
T, Sakamoto H. Cerebral dissecting aneurysms in patients 
with moyamoya disease. Report of two cases. J Neurosurg. 
1983;58(1):120–5. https:// doi. org/ 10. 3171/ jns. 1983. 58.1. 0120.
 44. Hori S, et al. Impact of interethnic difference of collateral angio-
architectures on prevalence of hemorrhagic stroke in Moyamoya 
disease. Neurosurgery. 2019;85(1):134–46. https:// doi. org/ 10. 
1093/ neuros/ nyy236.
 45. Kono S, Oka K, Sueishi K. Histopathologic and morphometric 
studies of leptomeningeal vessels in moyamoya disease. Stroke. 
1990;21(7):1044–50. https:// doi. org/ 10. 1161/ 01. str. 21.7. 1044.
 46. Ullrich NJ, et al. Moyamoya following cranial irradiation for pri-
mary brain tumors in children. Neurology. 2007;68(12):932–8. 
https:// doi. org/ 10. 1212/ 01. wnl. 00002 57095. 33125. 48.
 47. Yamada H, et al. The relationship between moyamoya disease 
and bacterial infection. Clin Neurol Neurosurg. 1997;99(Suppl 
2):S221–4. https:// doi. org/ 10. 1016/ s0303- 8467(97) 00048-6.
 48. Ueno M, Oka A, Koeda T, Okamoto R, Takeshita K. Unilateral 
occlusion of the middle cerebral artery after varicella-zoster 
virus infection. Brain Develop. 2002;24(2):106–8. https:// doi. 
org/ 10. 1016/ s0387- 7604(02) 00005-0.
 49. Tanigawara T, Yamada H, Sakai N, Andoh T, Deguchi K, 
Iwamura M. Studies on cytomegalovirus and Epstein-Barr 
virus infection in moyamoya disease. Clin Neurol Neurosurg. 
1997;99(Suppl 2):S225–8. https:// doi. org/ 10. 1016/ s0303- 
8467(97) 00049-8.
 50. Nanba R, Kuroda S, Tada M, Ishikawa T, Houkin K, Iwasaki Y. 
Clinical features of familial moyamoya disease. Child’s nervous 
system : ChNS : official journal of the International Society for 
Pediatric Neurosurgery. 2006;22(3):258–62. https:// doi. org/ 10. 
1007/ s00381- 005- 1230-5.
 51. Mineharu Y, et al. Inheritance pattern of familial moyamoya 
disease: autosomal dominant mode and genomic imprinting. J 
Neurol Neurosurg Psychiatry. 2006;77(9):1025–9. https:// doi. 
org/ 10. 1136/ jnnp. 2006. 096040.
 Translational Stroke Research
1 3
 52. Ahn HS, et al. Familial risk for Moyamoya disease among first-
degree relatives, based on a population-based aggregation study 
in Korea. Stroke. 2020;51(9):2752–60. https:// doi. org/ 10. 1161/ 
STROK EAHA. 120. 029251.
 53. Kraemer M, et al. Inheritance of moyamoya disease in a Cauca-
sian family. Eur J Neurol. 2012;19(3):438–42. https:// doi. org/ 10. 
1111/j. 1468- 1331. 2011. 03536.x.
 54. Grangeon L, et al. Clinical and molecular features of 5 European 
multigenerational families with moyamoya angiopathy. Stroke. 
2019;50(4):789–96. https:// doi. org/ 10. 1161/ STROK EAHA. 118. 
023972.
 55. Pulst SM. Genetic linkage analysis. Arch Neurol. 
1999;56(6):667–72. https:// doi. org/ 10. 1001/ archn eur. 56.6. 667.
 56. Ott J, Wang J, Leal SM. Genetic linkage analysis in the age of 
whole-genome sequencing. Nat Rev Genet. 2015;16(5):275–84. 
https:// doi. org/ 10. 1038/ nrg39 08.
 57. Ikeda H, Sasaki T, Yoshimoto T, Fukui M, Arinami T. Mapping 
of a familial moyamoya disease gene to chromosome 3p24.2-p26. 
Am J Hum Genet. 1999;64(2):533–7. https:// doi. org/ 10. 1086/ 
302243.
 58. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Link-
age analysis of moyamoya disease on chromosome 6. J Child 
Neurol. 2000;15(3):179–82. https:// doi. org/ 10. 1177/ 08830 73800 
01500 307.
 59. Sakurai K, et al. A novel susceptibility locus for moyamoya dis-
ease on chromosome 8q23. J Hum Genet. 2004;49(5):278–81. 
https:// doi. org/ 10. 1007/ s10038- 004- 0143-6.
 60. Yamauchi T, et al. Linkage of familial moyamoya disease (spon-
taneous occlusion of the circle of Willis) to chromosome 17q25. 
Stroke. 2000;31(4):930–5. https:// doi. org/ 10. 1161/ 01. str. 31.4. 
930.
 61. Nanba R, Tada M, Kuroda S, Houkin K, Iwasaki Y. Sequence 
analysis and bioinformatics analysis of chromosome 17q25 in 
familial moyamoya disease. Child’s Nerv Syst. 2005;21(1):62–8. 
https:// doi. org/ 10. 1007/ s00381- 004- 1005-4.
 62. Mineharu Y, et al. Autosomal dominant moyamoya disease maps 
to chromosome 17q25.3. Neurology. 2008;70(24 Pt 2):2357–63. 
https:// doi. org/ 10. 1212/ 01. wnl. 00002 91012. 49986. f9.
 63. Liu W, et al. A rare Asian founder polymorphism of Raptor 
may explain the high prevalence of Moyamoya disease among 
East Asians and its low prevalence among Caucasians. Environ 
Health Prev Med. 2010;15(2):94–104. https:// doi. org/ 10. 1007/ 
s12199- 009- 0116-7.
 64. Kamada F, et al. A genome-wide association study identifies 
RNF213 as the first Moyamoya disease gene. J Hum Genet. 
2011;56(1):34–40. https:// doi. org/ 10. 1038/ jhg. 2010. 132.
 65. Liu W, et al. Identification of RNF213 as a susceptibility gene 
for moyamoya disease and its possible role in vascular develop-
ment. PloS one. 2011;6(7):e22542. https:// doi. org/ 10. 1371/ journ 
al. pone. 00225 42.
 66. Altmüller J, Palmer LJ, Fischer G, Scherb H, Wjst M. Genom-
ewide scans of complex human diseases: true linkage is hard to 
find. Am J Hum Genet. 2001;69(5):936–50. https:// doi. org/ 10. 
1086/ 324069.
 67. Risch N, Merikangas K. The future of genetic studies of complex 
human diseases. Science. 1996;273(5281):1516–7. https:// doi. 
org/ 10. 1126/ scien ce. 273. 5281. 1516.
 68. Manolio TA. Genomewide association studies and assessment of 
the risk of disease. N Engl J Med. 2010;363(2):166–76. https:// 
doi. org/ 10. 1056/ NEJMr a0905 980.
 69. Madden K, Chabot-Richards D. HLA testing in the molecular 
diagnostic laboratory. Virchows Arch. 2019;474(2):139–47. 
https:// doi. org/ 10. 1007/ s00428- 018- 2501-3.
 70. Kitahara T, Okumura K, Semba A, Yamaura A, Makino H. 
Genetic and immunologic analysis on moya-moya. J Neurol 
Neurosurg Psychiatry. 1982;45(11):1048–52. https:// doi. org/ 
10. 1136/ jnnp. 45. 11. 1048.
 71. Aoyagi M, Ogami K, Matsushima Y, Shikata M, Yamamoto M, 
Yamamoto K. Human leukocyte antigen in patients with moy-
amoya disease. Stroke. 1995;26(3):415–7. https:// doi. org/ 10. 
1161/ 01. str. 26.3. 415.
 72. Inoue TK, Ikezaki K, Sasazuki T, Matsushima T, Fukui M. Anal-
ysis of class II genes of human leukocyte antigen in patients 
with moyamoya disease. Clin Neurol Neurosurg. 1997;99(Suppl 
2):S234–7. https:// doi. org/ 10. 1016/ s0303- 8467(97) 00051-6.
 73. Han H, Pyo C-W, Yoo D-S, Huh P-W, Cho K-S, Kim D-S. 
Associations of Moyamoya patients with HLA class I and 
class II alleles in the Korean population. J Korean Med Sci. 
2003;18(6):876–80. https:// doi. org/ 10. 3346/ jkms. 2003. 18.6. 
876.
 74. Hong SH, Wang K-C, Kim S-K, Cho B-K, Park MH. Association 
of HLA-DR and -DQ Genes with Familial Moyamoya Disease in 
Koreans. J Korean Neurosurg Soc. 2009;46(6):558–63. https:// 
doi. org/ 10. 3340/ jkns. 2009. 46.6. 558.
 75. Kraemer M, et al. Analysis of human leucocyte antigen genes 
in Caucasian patients with idiopathic moyamoya angiopathy. 
Acta Neurochir. 2012;154(3):445–54. https:// doi. org/ 10. 1007/ 
s00701- 011- 1261-5.
 76. Tashiro R, et al. Identification of HLA-DRB1*04:10 allele as 
risk allele for Japanese moyamoya disease and its association 
with autoimmune thyroid disease: A case-control study. PloS 
One. 2019;14(8):e0220858. https:// doi. org/ 10. 1371/ journ al. pone. 
02208 58.
 77. Holoshitz J. The quest for better understanding of HLA-disease 
association: scenes from a road less travelled by. Discov Med. 
2013;16(87):93–101.
 78. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N 
Engl J Med. 1993;329(27):2002–12. https:// doi. org/ 10. 1056/ 
NEJM1 99312 30329 2706.
 79. Moro MA, Cárdenas A, Hurtado O, Leza JC, Lizasoain I. Role 
of nitric oxide after brain ischaemia. Cell Calcium. 2004;36(3–
4):265–75. https:// doi. org/ 10. 1016/j. ceca. 2004. 02. 011.
 80. Park YS, et al. Age-specific eNOS polymorphisms in moyamoya 
disease. Child’s Nerv Syst. 2011;27(11):1919–26. https:// doi. org/ 
10. 1007/ s00381- 011- 1504-z.
 81. Rempe RG, Hartz AMS, Bauer B. Matrix metalloproteinases in 
the brain and blood-brain barrier: Versatile breakers and makers. 
J Cereb Blood Flow Metab. 2016;36(9):1481–507. https:// doi. 
org/ 10. 1177/ 02716 78X16 655551.
 82. Lo EH, Dalkara T, Moskowitz MA. Mechanisms, challenges and 
opportunities in stroke. Nat Rev Neurosci. 2003;4(5):399–415. 
https:// doi. org/ 10. 1038/ nrn11 06.
 83. Blecharz-Lang KG, et al. Gelatinolytic activity of autocrine 
matrix metalloproteinase-9 leads to endothelial de-arrange-
ment in Moyamoya disease. J Cereb Blood Flow Metab. 
2018;38(11):1940–53. https:// doi. org/ 10. 1177/ 02716 78X18 
768443.
 84. Kang H-S, Kim S-K, Cho B-K, Kim Y-Y, Hwang Y-S, Wang 
K-C. Single nucleotide polymorphisms of tissue inhibitor of 
metalloproteinase genes in familial moyamoya disease. Neuro-
surgery. 2006;58(6):1074–80. https:// doi. org/ 10. 1227/ 01. NEU. 
00002 15854. 66011. 4F.
 85. Paez MT, Yamamoto T. “Single nucleotide polymorphisms of 
tissue inhibitor of metalloproteinase genes in familial moyamoya 
disease.,” Neurosurgery, vol. 60, no. 3. United States, pp. E582; 
author reply E582, Mar. 2007. https:// doi. org/ 10. 1227/ 01. NEU. 
00002 55365. 25066. CD.
 86. Roder C, et al. Common genetic polymorphisms in moyamoya 
and atherosclerotic disease in Europeans. Child’s Nerv Syst. 
2011;27(2):245–52. https:// doi. org/ 10. 1007/ s00381- 010- 1241-8.
Translational Stroke Research 
1 3
 87. Li H, et al. Association of a functional polymorphism in the 
MMP-3 gene with Moyamoya Disease in the Chinese Han popu-
lation. Cerebrovasc Dis (Basel, Switzerland). 2010;30(6):618–
25. https:// doi. org/ 10. 1159/ 00031 9893.
 88. Wang X, et al. Impacts and interactions of PDGFRB, MMP-3, 
TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya 
disease in Han Chinese human subjects. Gene. 2013;526(2):437–
42. https:// doi. org/ 10. 1016/j. gene. 2013. 05. 083.
 89. Park YS, et  al. The GC + CC genotype at position -418 in 
TIMP-2 promoter and the -1575GA/-1306CC genotype in 
MMP-2 is genetic predisposing factors for prevalence of moy-
amoya disease. BMC Neurol. 2014;14:180. https:// doi. org/ 10. 
1186/ s12883- 014- 0180-5.
 90. Ma J, You C. Association between matrix metalloproteinase-3 
gene polymorphism and moyamoya disease. J Clin Neurosci. 
2015;22(3):479–82. https:// doi. org/ 10. 1016/j. jocn. 2014. 08. 034.
 91. Wang X, et  al. Association of genetic variants with moy-
amoya disease in 13 000 individuals: a meta-analysis. Stroke. 
2020;51(6):1647–55. https:// doi. org/ 10. 1161/ STROK EAHA. 
120. 029527.
 92. Sakamoto S, et al. “Expression of vascular endothelial growth 
factor in dura mater of patients with moyamoya disease.,” Neu-
rosurg Rev. 31(1):77–81; discussion 81, Jan. 2008. https:// doi. 
org/ 10. 1007/ s10143- 007- 0102-8.
 93. Rafat N, Beck GC, Peña-Tapia PG, Schmiedek P, Vajkoczy P. 
Increased levels of circulating endothelial progenitor cells in 
patients with Moyamoya disease. Stroke. 2009;40(2):432–8. 
https:// doi. org/ 10. 1161/ STROK EAHA. 108. 529420.
 94. Kang H-S, et al. Plasma matrix metalloproteinases, cytokines 
and angiogenic factors in moyamoya disease. J Neurol Neurosurg 
Psychiatry. 2010;81(6):673–8. https:// doi. org/ 10. 1136/ jnnp. 2009. 
191817.
 95. Apte RS, Chen DS, Ferrara N. VEGF in signaling and disease: 
beyond discovery and development. Cell. 2019;176(6):1248–64. 
https:// doi. org/ 10. 1016/j. cell. 2019. 01. 021.
 96. Melincovici CS, et al. Vascular endothelial growth factor (VEGF) 
- key factor in normal and pathological angiogenesis. Roman J 
Morphol Embryol. 2018;59(2):455–67.
 97. Park YS, et al. The role of VEGF and KDR polymorphisms in 
moyamoya disease and collateral revascularization. PloS One. 
2012;7(10):e47158. https:// doi. org/ 10. 1371/ journ al. pone. 00471 
58.
 98. He J, Wang R, Zhang D, Zhang Y, Zhang Q, Zhao J. Expression 
of circulating vascular endothelial growth factor-antagonizing 
cytokines and vascular stabilizing factors prior to and following 
bypass surgery in patients with moyamoya disease. Exp Ther 
Med. 2014;8(1):302–8. https:// doi. org/ 10. 3892/ etm. 2014. 1713.
 99. Gaengel K, Genové G, Armulik A, Betsholtz C. Endothelial-
mural cell signaling in vascular development and angiogenesis. 
Arterioscler Thromb Vasc Biol. 2009;29(5):630–8. https:// doi. 
org/ 10. 1161/ ATVBA HA. 107. 161521.
 100. Kemp SS, Aguera KN, Cha B, Davis GE. Defining endothe-
lial cell-derived factors that promote pericyte recruitment and 
capillary network assembly. Arterioscler Thromb Vasc Biol. 
2020;40(11):2632–48. https:// doi. org/ 10. 1161/ ATVBA HA. 120. 
314948.
 101. Heldin CH, Westermark B. Mechanism of action and in vivo role 
of platelet-derived growth factor. Physiol Rev. 1999;79(4):1283–
316. https:// doi. org/ 10. 1152/ physr ev. 1999. 79.4. 1283.
 102. Aoyagi M, et al. Altered cellular responses to serum mitogens, 
including platelet-derived growth factor, in cultured smooth 
muscle cells derived from arteries of patients with moyamoya 
disease. J Cell Physiol. 1991;147(2):191–8. https:// doi. org/ 10. 
1002/ jcp. 10414 70202.
 103. Aoyagi M, Fukai N, Matsushima Y, Yamamoto M, Yamamoto K. 
Kinetics of 125I-PDGF binding and down-regulation of PDGF 
receptor in arterial smooth muscle cells derived from patients 
with moyamoya disease. J Cell Physiol. 1993;154(2):281–8. 
https:// doi. org/ 10. 1002/ jcp. 10415 40210.
 104. Roder C, et al. Polymorphisms in TGFB1 and PDGFRB are 
associated with Moyamoya disease in European patients. Acta 
Neurochir. 2010;152(12):2153–60. https:// doi. org/ 10. 1007/ 
s00701- 010- 0711-9.
 105. Hojo M, et  al. Role of transforming growth factor-beta1 
in the pathogenesis of moyamoya disease. J Neurosurg. 
1998;89(4):623–9. https:// doi. org/ 10. 3171/ jns. 1998. 89.4. 0623.
 106. Liu C, et al. Analysis of TGFB1 in European and Japanese Moy-
amoya disease patients. Eur J Med Genet. 2012;55(10):531–4. 
https:// doi. org/ 10. 1016/j. ejmg. 2012. 05. 002.
 107. Park YS, et  al. Association of the miR-146aC>G, miR-
196a2C>T, and miR-499A>G polymorphisms with moyamoya 
disease in the Korean population. Neurosci Lett. 2012;521(1):71–
5. https:// doi. org/ 10. 1016/j. neulet. 2012. 05. 062.
 108. Kawasaki T, et al. Three Cases of Moyamoya Disease with a 
History of Kawasaki Disease. No shinkei geka Neurol Surg. 
2015;43(11):1005–10. https:// doi. org/ 10. 11477/ mf. 14362 03169.
 109. Shen W, Liao Y, Garcia R, Kesavabhotla K, Xu B, Li H. Asso-
ciation of CD40 SNPs with Moyamoya in a Chinese children 
population. Br J Neurosurg. 2019;33(4):398–401. https:// doi. org/ 
10. 1080/ 02688 697. 2018. 15592 75.
 110. Yang Y, et al. PHACTR1 is associated with disease progression 
in Chinese Moyamoya disease. PeerJ. 2020;8:e8841. https:// doi. 
org/ 10. 7717/ peerj. 8841.
 111. Shoemaker LD, et al. Disease Variant Landscape of a Large Mul-
tiethnic Population of Moyamoya Patients by Exome Sequencing. 
G3 (Bethesda, Md). 2016;6(1):41–9. https:// doi. org/ 10. 1534/ g3. 
115. 020321.
 112. Pinard A, et al. The pleiotropy associated with de novo variants 
in CHD4, CNOT3, and SETD5 extends to moyamoya angiopa-
thy. Genet Med. 2020;22(2):427–31. https:// doi. org/ 10. 1038/ 
s41436- 019- 0639-2.
 113. Peng X, et al. Gene dysregulation in peripheral blood of moy-
amoya disease and comparison with other vascular disorders. 
PloS One. 2019;14(9):e0221811. https:// doi. org/ 10. 1371/ journ 
al. pone. 02218 11.
 114. Aloui C, et al. Xq28 copy number gain causing moyamoya disease 
and a novel moyamoya syndrome. J Med Genet. 2020;57(5):339–
46. https:// doi. org/ 10. 1136/ jmedg enet- 2019- 106525.
 115. Kundishora AJ, et al. DIAPH1 variants in non-east asian patients 
with sporadic moyamoya disease. JAMA Neurol. 2021. https:// 
doi. org/ 10. 1001/ jaman eurol. 2021. 1681.
 116. Morito D, et al. Moyamoya disease-associated protein mysterin/
RNF213 is a novel AAA+ ATPase, which dynamically changes 
its oligomeric state. Sci Rep. 2014;4:4442. https:// doi. org/ 10. 
1038/ srep0 4442.
 117. Kim E-H, et al. Importance of RNF213 polymorphism on clinical 
features and long-term outcome in moyamoya disease. J Neuro-
surg. 2016;124(5):1221–7. https:// doi. org/ 10. 3171/ 2015.4. JNS14 
2900.
 118. Miyatake S, et al. Homozygous c.14576G>A variant of RNF213 
predicts early-onset and severe form of moyamoya disease. 
Neurology. 2012;78(11):803–10. https:// doi. org/ 10. 1212/ WNL. 
0b013 e3182 49f71f.
 119. Moteki Y, et al. Systematic validation of RNF213 coding variants 
in Japanese patients with moyamoya disease. J Am Heart Assoc. 
2015. https:// doi. org/ 10. 1161/ JAHA. 115. 001862
 120. Zhang Q, et al. RNF213 as the major susceptibility gene for Chi-
nese patients with moyamoya disease and its clinical relevance. 
J Neurosurg. 2017;126(4):1106–13. https:// doi. org/ 10. 3171/ 
2016.2. JNS15 2173.
 121. Duan L, et  al. Novel susceptibility loci for moyamoya dis-
ease revealed by a genome-wide association study. Stroke. 
 Translational Stroke Research
1 3
2018;49(1):11–8. https:// doi. org/ 10. 1161/ STROK EAHA. 117. 
017430.
 122. Wang Y, et al. Predictive role of heterozygous p. R4810K of 
RNF213 in the phenotype of Chinese moyamoya disease. Neurol-
ogy. 2020;94(7):e678–86. https:// doi. org/ 10. 1212/ WNL. 00000 
00000 008901.
 123. Park YS, et al. “The role of RNF213 4810G>A and 4950G>A 
variants in patients with moyamoya disease in Korea.” Int J Mol 
Sci. 2017;18(11). https:// doi. org/ 10. 3390/ ijms1 81124 77.
 124. Jang M-A, Shin S, Yoon JH, Ki C-S. Frequency of the moy-
amoya-related RNF213 p.Arg4810Lys variant in 1,516 Korean 
individuals. BMC Med Genet. 2015;16:109. https:// doi. org/ 10. 
1186/ s12881- 015- 0252-4.
 125. Nomura S, et al. Genotype-Phenotype Correlation in Long-Term 
Cohort of Japanese Patients with Moyamoya Disease. Cerebro-
vasc Dis (Basel, Switzerland). 2019;47(3–4):105–11. https:// doi. 
org/ 10. 1159/ 00049 9699.
 126. Jang M-A, et al. Frequency and significance of rare RNF213 
variants in patients with adult moyamoya disease. PloS one. 
2017;12(6):e0179689. https:// doi. org/ 10. 1371/ journ al. pone. 
01796 89.
 127. Wu Z, et  al. Molecular analysis of RNF213 gene for moy-
amoya disease in the Chinese Han population. PloS one. 
2012;7(10):e48179. https:// doi. org/ 10. 1371/ journ al. pone. 00481 
79.
 128. Liao X, Deng J, Dai W, Zhang T, Yan J. Rare variants of RNF213 
and moyamoya/non-moyamoya intracranial artery stenosis/occlu-
sion disease risk: a meta-analysis and systematic review. Envi-
ron Health Prev Med. 2017;22(1):75. https:// doi. org/ 10. 1186/ 
s12199- 017- 0680-1.
 129. Cecchi AC, et al. RNF213 rare variants in an ethnically diverse 
population with Moyamoya disease. Stroke. 2014;45(11):3200–
7. https:// doi. org/ 10. 1161/ STROK EAHA. 114. 006244.
 130. Liu W, et al. Genomewide association study identifies no major 
founder variant in Caucasian moyamoya disease. J Genet. 
2013;92(3):605–9. https:// doi. org/ 10. 1007/ s12041- 013- 0304-5.
 131. Smith KR, et al. “Identification of a novel RNF213 variant in 
a family with heterogeneous intracerebral vasculopathy.” Int J 
Stroke. 2014;9(6). United States, pp. E26–7. https:// doi. org/ 10. 
1111/ ijs. 12306.
 132. Raso A, et al. Moyamoya vasculopathy shows a genetic muta-
tional gradient decreasing from East to West. J Neurosurg Sci. 
2020;64(2):165–72. https:// doi. org/ 10. 23736/ S0390- 5616. 16. 
03900-X.
 133. Gagunashvili AN, et  al. Novel missense variants in the 
RNF213 gene from a European family with Moyamoya dis-
ease. Hum Genome Var. 2019;6:35. https:// doi. org/ 10. 1038/ 
s41439- 019- 0066-6.
 134. Pinard A, et al. Association of de novo RNF213 variants with 
childhood onset moyamoya disease and diffuse occlusive vascu-
lopathy. Neurology. 2021;96(13):e1783–91. https:// doi. org/ 10. 
1212/ WNL. 00000 00000 011653.
 135. Kobayashi H, et al. RNF213 rare variants in Slovakian and Czech 
moyamoya disease patients. PloS one. 2016;11(10):e0164759. 
https:// doi. org/ 10. 1371/ journ al. pone. 01647 59.
 136. Guey S, et al. Rare RNF213 variants in the C-terminal region 
encompassing the RING-finger domain are associated with 
moyamoya angiopathy in Caucasians. Eur J Hum Genet. 
2017;25(8):995–1003. https:// doi. org/ 10. 1038/ ejhg. 2017. 92.
 137. Miyawaki S, Imai H, Takayanagi S, Mukasa A, Nakatomi H, 
Saito N. Identification of a genetic variant common to moyamoya 
disease and intracranial major artery stenosis/occlusion. Stroke. 
2012;43(12):3371–4. https:// doi. org/ 10. 1161/ STROK EAHA. 
112. 663864.
 138. Ma J, Liu Y, Ma L, Huang S, Li H, You C. RNF213 polymor-
phism and Moyamoya disease: A systematic review and meta-
analysis. Neurol India. 2013;61(1):35–9. https:// doi. org/ 10. 4103/ 
0028- 3886. 107927.
 139. Huang Y, Cheng D, Zhang J, Zhao W. Association between the 
rs112735431 polymorphism of the RNF213 gene and moyamoya 
disease: a case-control study and meta-analysis. J Clin Neurosci. 
2016;32:14–8. https:// doi. org/ 10. 1016/j. jocn. 2015. 11. 035.
 140. Lee M-J, et al. Mutation genotypes of RNF213 gene from moy-
amoya patients in Taiwan. J Neurol Sci. 2015;353(1–2):161–5. 
https:// doi. org/ 10. 1016/j. jns. 2015. 04. 019.
 141. Liu W, Hitomi T, Kobayashi H, Harada KH, Koizumi A. Dis-
tribution of moyamoya disease susceptibility polymorphism p. 
R4810K in RNF213 in East and Southeast Asian populations. 
Neurol Med Chir. 2012;52(5):299–303. https:// doi. org/ 10. 2176/ 
nmc. 52. 299.
 142. Koizumi A, Kobayashi H, Hitomi T, Harada KH, Habu T, 
Youssefian S. A new horizon of moyamoya disease and 
associated health risks explored through RNF213. Environ 
Health Prev Med. 2016;21(2):55–70. https:// doi. org/ 10. 1007/ 
s12199- 015- 0498-7.
 143. MacArthur DG, et  al. Guidelines for investigating cau-
sality of sequence variants in human disease. Nature. 
2014;508(7497):469–76. https:// doi. org/ 10. 1038/ natur e13127.
 144. Miyatake S, et al. Sibling cases of moyamoya disease having 
homozygous and heterozygous c.14576G>A variant in RNF213 
showed varying clinical course and severity. J Hum Genet. 
2012;57(12):804–6. https:// doi. org/ 10. 1038/ jhg. 2012. 105.
 145. Kim W-H, et al. Posterior circulation involvement and collateral 
flow pattern in moyamoya disease with the RNF213 polymor-
phism. Child’s Nerv Syst. 2019;35(2):309–14. https:// doi. org/ 10. 
1007/ s00381- 018- 3985-5.
 146. Ge P, et al. Association Between p. R4810K Variant and Long-
Term Clinical Outcome in Patients With Moyamoya Disease. 
Front Neurol. 2019;10:662. https:// doi. org/ 10. 3389/ fneur. 2019. 
00662.
 147. Ge P, et al. Different subtypes of collateral vessels in hemor-
rhagic moyamoya disease with p. R4810K variant. BMC Neurol. 
2020;20(1):308. https:// doi. org/ 10. 1186/ s12883- 020- 01884-0.
 148. Ge P, et al. Association between p. R4810K Variant and Post-
operative Collateral Formation in Patients with Moyamoya Dis-
ease. Cerebrovasc Dis (Basel, Switzerland). 2019;48(1–2):77–84. 
https:// doi. org/ 10. 1159/ 00050 3250.
 149. Lin J, Sheng W. RNF213 Variant Diversity Predisposes Distinct 
Populations to Dissimilar Cerebrovascular Diseases. Biomed Res 
Int. 2018;2018:6359174. https:// doi. org/ 10. 1155/ 2018/ 63591 74.
 150. Sirui, Zhou Amirthagowri, Ambalavanan Daniel, Rochefort 
Pingxing, Xie Cynthia V., Bourassa Pascale, Hince Alexandre, 
Dionne-Laporte Dan, Spiegelman Ziv, Gan-Or Cathy, Mirarchi 
Vessela, Zaharieva Nicolas, Dupré Hatasu, Kobayashi Toshiaki, 
Hitomi Kouji, Harada Akio, Koizumi Lan, Xiong Patrick A., 
Dion Guy A., Rouleau (2016) RNF213 Is Associated with Intrac-
ranial Aneurysms in the French-Canadian Population. Am J Hum 
Genet 99(5):1072–1085. https:// doi. org/ 10. 1016/j. ajhg. 2016. 09. 
001.
 151. Kim HJ, et al. Role of the RNF213 Variant in vascular outcomes 
in patients with intracranial atherosclerosis. J Am Heart Assoc. 
2021;10(1):e017660. https:// doi. org/ 10. 1161/ JAHA. 120. 017660.
 152. Hiraide T, et al. Poor outcomes in carriers of the RNF213 variant 
(p.Arg4810Lys) with pulmonary arterial hypertension. J Heart 
Lung Transplant. 2020;39(2):103–12. https:// doi. org/ 10. 1016/j. 
healun. 2019. 08. 022.
 153. Sonobe S, et al. Temporal profile of the vascular anatomy evalu-
ated by 9.4-T magnetic resonance angiography and histopatho-
logical analysis in mice lacking RNF213: a susceptibility gene 
Translational Stroke Research 
1 3
for moyamoya disease. Brain Res. 2014;1552:64–71. https:// doi. 
org/ 10. 1016/j. brain res. 2014. 01. 011.
 154. Ito A, et al. Enhanced post-ischemic angiogenesis in mice lacking 
RNF213; a susceptibility gene for moyamoya disease. Brain Res. 
2015;1594:310–20. https:// doi. org/ 10. 1016/j. brain res. 2014. 11. 
014.
 155. Kanoke A, et  al. Temporal profile of the vascular anatomy 
evaluated by 9.4-tesla magnetic resonance angiography and 
histological analysis in mice with the R4859K mutation of 
RNF213, the susceptibility gene for moyamoya disease. Brain 
Res. 2015;1624:497–505. https:// doi. org/ 10. 1016/j. brain res. 
2015. 07. 039.
 156. Morimoto T, et al. Dysregulation of RNF213 promotes cerebral 
hypoperfusion. Sci Rep. 2018;8(1):3607. https:// doi. org/ 10. 1038/ 
s41598- 018- 22064-8.
 157. Hitomi T, et  al. Downregulation of Securin by the variant 
RNF213 R4810K (rs112735431, G>A) reduces angiogenic 
activity of induced pluripotent stem cell-derived vascular 
endothelial cells from moyamoya patients. Biochem Biophys 
Res Commun. 2013;438(1):13–9. https:// doi. org/ 10. 1016/j. bbrc. 
2013. 07. 004.
 158. Hamauchi S, et  al. Cellular functions and gene and protein 
expression profiles in endothelial cells derived from moyamoya 
disease-specific iPS cells. PloS One. 2016;11(9):e0163561. 
https:// doi. org/ 10. 1371/ journ al. pone. 01635 61.
 159. Cardano M, et al. Establishment of induced pluripotent stem 
cell (iPSC) line from 55-year old male patient with hemorrhagic 
Moyamoya disease. Stem Cell Res. 2016;17(3):623–6. https:// 
doi. org/ 10. 1016/j. scr. 2016. 11. 006.
 160. Cardano M, et al. Establishment of induced pluripotent stem 
cell (iPSC) line from an 8-year old female patient with ischemic 
Moyamoya disease. Stem Cell Res. 2016;17(3):619–22. https:// 
doi. org/ 10. 1016/j. scr. 2016. 11. 007.
 161. Uchino H, et al. Circulating miRNome profiling in Moyamoya 
disease-discordant monozygotic twins and endothelial microRNA 
expression analysis using iPS cell line. BMC Med Genom. 
2018;11(1):72. https:// doi. org/ 10. 1186/ s12920- 018- 0385-3.
 162. Tokairin K, et al. Vascular smooth muscle cell derived from 
IPS cell of moyamoya disease - comparative characterization 
with endothelial cell transcriptome. J Stroke Cerebrovasc Dis. 
2020;29(12):105305. https:// doi. org/ 10. 1016/j. jstro kecer ebrov 
asdis. 2020. 105305.
 163. Hitomi T, et al. The moyamoya disease susceptibility variant 
RNF213 R4810K (rs112735431) induces genomic instabil-
ity by mitotic abnormality. Biochem Biophys Res Commun. 
2013;439(4):419–26. https:// doi. org/ 10. 1016/j. bbrc. 2013. 08. 067.
 164. Ohkubo K, et al. Moyamoya disease susceptibility gene RNF213 
links inflammatory and angiogenic signals in endothelial cells. 
Sci Rep. 2015;5:13191. https:// doi. org/ 10. 1038/ srep1 3191.
 165. Kanoke A, et al. Temporal profile of magnetic resonance angiog-
raphy and decreased ratio of regulatory T cells after immunologi-
cal adjuvant administration to mice lacking RNF213, a suscep-
tibility gene for moyamoya disease. Brain Res. 2016;1642:1–9. 
https:// doi. org/ 10. 1016/j. brain res. 2016. 03. 009.
 166. Kobayashi H, et al. “Biochemical and functional characteriza-
tion of RNF213 (Mysterin) R4810K, a susceptibility mutation 
of moyamoya disease, in angiogenesis in vitro and in vivo.” J 
Am Heart Assoc. 2015;4(7). https:// doi. org/ 10. 1161/ JAHA. 115. 
002146.
 167. Sonobe S, et al. Increased vascular MMP-9 in mice lacking 
RNF213: moyamoya disease susceptibility gene. NeuroReport. 
2014;25(18):1442–6. https:// doi. org/ 10. 1097/ WNR. 00000 00000 
000289.
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
